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3ABSTRACT
Transport proteins embedded in the cell membranes of many organs can affect
the absorption, distribution and elimination of numerous drugs. This can lead
to the enhanced or restricted uptake or distribution of  the drugs,  nonlinear
pharmacokinetics, transporter-mediated drug-drug interactions (DDIs) and
inter-individual variability. Transporters may therefore alter the safety and
efficacy of drugs, thus it is important to study drug-transporter interactions in
drug development.
The  breast  cancer  resistance  protein  (BCRP,  ABCG2)  is  one  of  the
transporters involved in drug disposition. It belongs to the ATP-binding
cassette  (ABC)  transporter  family  and  uses  ATP  to  expel  drugs  and  other
substrates out from cells. BCRP was initially found to cause drug resistance in
cancer cell lines, but it is also expressed in healthy tissues such as the intestine,
liver and blood-brain barrier, where it is one of the transporters limiting the
uptake of many structurally diverse compounds. Despite interest in BCRP and
other ABC transporters, it remains poorly understood how they recognize their
substrates  and  which  chemical  structures  are  liable  to  interaction.  In  this
thesis, a vesicle-based in vitro method  was  used  to  study  the  ligand
preferences of BCRP. The results were compared to those obtained for the
multidrug  resistance  associated  protein  2  (MRP2,  ABCC2),  which  is  also
implicated  in  drug  transport.  The  results  show  that  a  range  of  natural
compounds  and  their  derivatives  are  able  to  inhibit  BCRP  transport  and
among  these,  flavonoids  were  identified  as  the  most  important  group  for
inhibition. Conversely, MRP2 transport was affected by only few of the tested
compounds.  However,  a  more similar pattern of  inhibition was seen for the
two transporters when selected food additives were studied, where several
food  colourants  were  identified  as  inhibitors.  In  addition,  the  effect  of  one
assay  component  (bovine  serum  albumin,  BSA)  on  the in vitro transport
kinetics of BCRP and MRP2 was evaluated. The inclusion of BSA in the vesicle
assay  lead  to  moderate  changes  (up  to  2-fold)  in  transport  activity,  but  the
effects on in vitro − in vivo extrapolation are expected to be minor, at least
based on the tested compounds. Finally, the vesicle assay was used to study
the  functionality  of  selected  BCRP  variants  with  polymorphisms  in  the
transmembrane  helices  and  they  were  found  to  have  significantly  impaired
transport activity and expression compared to wild type BCRP.
In summary, the vesicle-based transport assay was applied to identify and
evaluate the effects that BCRP interactions may have on the pharmacokinetics
of BCRP substrates.
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1 INTRODUCTION
The development of a new drug is an immensely time-consuming and costly
process with a high likelihood of failure. This can be explained partly by the
many different requirements that a successful drug candidate must fulfil.  In
addition to pharmacological potency, a drug must have sufficient exposure at
its target site to be able to exert its effects (Morgan et al., 2012). For an oral
drug, this means that the drug must be first absorbed and then distributed in
the body to reach its target tissue. After eliciting its desired effect, the drug
must be eliminated.
Drugs (and other molecules) distribute to tissues from the blood circulation
by passing through cell membranes. One factor affecting the absorption and
distribution of drugs are transport proteins embedded in the cell membranes
of  tissues throughout the body (Giacomini  et  al.,  2010).  The involvement of
transporters in drug disposition may lead to nonlinear pharmacokinetics (PK),
transporter-mediated drug-drug interactions (DDIs) as well as inter-
individual variability. Thus, transporters, much like metabolic enzymes, can
alter the safety and efficacy of drugs. Therefore, the interactions between new
drug  molecules  and  selected  transporters  should  be  studied  during  drug
development  (European  Medicines  Agency,  2012;  US  Food  and  Drug
Administration, 2012). Understanding of transporter interactions may also
facilitate the elucidation of the mechanisms of DDIs between drugs that are
already on the market.
Despite the increasing number of drug−transporter interactions being
recognized in vitro, and to a smaller extent in vivo, the interaction potential of
a compound as well as its consequences are difficult to predict. Additionally,
there are still many unanswered questions about the physiological functions
and genetic variability of the identified drug transporters. These transporters
exhibit broad and often overlapping capabilities to interact with different
compounds, which increases the challenge of elucidating the properties of a
single transporter on observed in vivo PK events.
This thesis describes the evaluation of the interactions of the drug efflux
transporter  ABCG2,  known as  the  breast  cancer  resistance  protein  (BCRP),
using a vesicle-based in vitro technique. The technique was applied to study
the  inhibition  of  BCRP  and  the  multidrug  resistance  associated  protein  2
(MRP2,  ABCC2)  by  natural  compounds  and  their  derivatives  as  well  as
selected food additives. Genetic variants of BCRP were also generated and the
same  method  was  used  to  investigate  the  effects  of  the  polymorphisms  on
BCRP transport activity. The utility of the vesicle-based assay to study
transporter interactions and the implications of the in vitro findings to the
clinical setting are discussed.
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2 REVIEW OF THE LITERATURE
Transport proteins, or transporters, can be categorized into two major
families, the solute carrier (SLC) family and the ATP-binding cassette (ABC)
family. SLC transporters mediate the movement of molecules across the cell
membrane, either by facilitated diffusion or by using ion or electrochemical
gradients (Lin et al., 2015). ABC transporters, on the other hand, use ATP to
drive transport irrespective of concentration gradients. Transporters are also
characterised by the direction of transport that they mediate: influx
transporters pump their substrates into cells, whereas efflux transporters
expel molecules out from cells.
This thesis concentrates on two efflux transporters of the ABC family. ABC
transporters are structurally characterized by nucleotide-binding domains
(NBDs)  that  contain  the  so  called  Walker  A  and  Walker  B  motifs  and  a
signature  C  motif  (Dean  et  al.,  2001).  Typically  two  of  these  domains  are
present and they form the basis for ATP hydrolysis. In addition to these, the
basic structure also includes two transmembrane domains (TMDs), each with
typically six transmembrane helices. The composition of these
transmembrane domains are responsible for determining the substrate
specificity and function of the transporters. Some members deviate from the
typical TMD-NBD-TMD-NBD structure and have an additional
transmembrane domain (e.g. ABCC1) or may completely lack these domains
(ABCE  and  ABCF  family  members)(Dean  et  al.,  2001).  Others,  such  as  the
ABCG family members, consist of only half of the required elements and must,
thus, form homodimers or heterodimers to function.
The ABC transporter family consists of 48 members in 7 subfamilies named
from A to G. Most of the human ABC proteins are efflux transporters, but their
roles  and  localisation  in  the  cell  are  diverse  (Dean  et  al.,  2001).  ABC
transporters are involved in the transport of cholesterol, vitamin A, bile acids,
long chain fatty acids as well as drugs, to name a few. In addition to this, some
family members function as receptors or ion channels. ABC transporters are
important  for  homeostasis  and  mutations  in  several  ABC transporters  have
been linked to disease. For example, some ABCB variants are associated with
progressive familial intrahepatic cholestasis, whereas variants of ABCA4 can
cause  visual  impairment  due  to  disrupted  transport  in  photoreceptor  cells.
Moreover,  cystic  fibrosis  is  caused  by  the  dysfunction  of  ABCC7,  the  cystic
fibrosis transmembrane conductance regulator (CFTR).
Regarding  drug  transport,  the  most  important  subfamilies  are  ABCB,
ABCC, and ABCG. Members from these families, especially efflux transporters
ABCB1, ABCC2, and ABCG2, interact with a wide variety of drugs and drug-
like  compounds  (Matsson  et  al.,  2009).  Other  ABCC  transporters,  termed
multidrug resistance associated proteins (MRPs), such as MRP1, MRP3, and
MRP4, as well as ABCB11 (bile salt export pump, BSEP) which is involved in
Review of the literature
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bile salt extrusion, can also interact with xenobiotics, and might thus  affect
drug disposition or toxicity (Hillgren et al., 2013; Pedersen et al., 2013).
ABCB1,  known  as  the  multidrug  resistance  protein  1  (MDR1)  or  P-
glycoprotein, was the first to be cloned and is the most exhaustively studied of
the ABC drug transporters. The persisting, though unofficial, nomenclature
still reflects the history of these drug transporters that were initially identified
in  multidrug  resistant  cancer  cell  lines.  This  is  despite  the  fact  that  these
interactions may be less important than their role in overall drug disposition
and PK in the body. The influence of ABC transporters on drug PK is a result
of  their  expression  in  tissues  that  are  important  for  absorption  and
elimination,  namely  the  intestine,  liver,  and  kidney.  In  these  tissues,  ABC
transporters  work  together  with  metabolic  enzymes  and  contribute  to  the
transport of drugs and other compounds that have undergone Phase I and/or
Phase II metabolism (Doring & Petzinger, 2014).
In the following review, the two ABC transporters that are the main focus
of this thesis, breast cancer resistance protein (BCRP, ABCG2) and multidrug
resistance associated protein 2 (MRP2, ABCC2) will  be described in further
detail.
2.1 BREAST CANCER RESISTANCE PROTEIN (BCRP)
The  ABC  family  submember  G2  was  originally  identified  in  multidrug-
resistant cell lines of breast cancer and colon carcinoma (Doyle et al.,  1998;
Miyake et al., 1999), and in human placenta (Allikmets et al., 1998). This led
to heterogeneous nomenclature, including breast cancer resistance protein
(BCRP), mitoxantrone resistance protein (MXR) and ABC placenta protein
(ABCP). BCRP has become the most commonly used non-standard name for
ABCG2, however, and will be used from here on throughout this thesis.
The structure of BCRP, like other ABCG transporters, deviates from the
basic ABC transporter structure, which consists of two TMDs and two NBDs.
BCRP is often referred to as a “half-transporter”, because the ABCG2 gene only
encodes  for  a  655  amino  acid  long  (72  kDa)  protein  that  has  six
transmembrane  helices  in  one  TMD  and  only  one  NBD  (Figure  1A).
Additionally, the order of the elements is reversed; the NBD at the N-terminus
precedes the TMD (Doyle et al., 1998). Due to its half-structure, BCRP must
form oligomers, either homodimers or higher order homomeric complexes, to
be able to perform its transport function (Xu et al., 2004; Ni et al., 2010; Wong
et al., 2016).
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Figure 1 (A) Membrane topology of BCRP and (B) molecular structures of selected
substrates
Despite originally being identified in cancer cell lines, BCRP is expressed
ubiquitously in the body on the apical membranes of cells (Maliepaard et al.,
2001), much like P-glycoprotein. BCRP is found in the canalicular membranes
of the liver and proximal tubules of the kidney (Maliepaard et al., 2001; Huls
et al., 2008), where it enhances the excretion of its substrates into the bile and
urine, respectively. In barrier tissues such as the intestinal epithelium,
placental syncytiotrophoblastic cells, and the blood-brain barrier, BCRP limits
the entry of  molecules (Maliepaard et  al.,  2001;  Cooray et  al.,  2002).  BCRP
may also have a protective role in undifferentiated human embryonic stem cell
lines, although the expression is decreased and lost during differentiation
(Apati et al., 2008).
Many proteomic studies have concentrated on quantifying drug
transporters in the intestine and liver, due to the importance of these tissues
to the overall  PK of  drugs.  According to the study by Drozdzik et  al.  (2014)
BCRP  contributed  4%  to  the  total  expression  of  10  clinically  relevant
transporters studied in human intestinal samples. Conversely, BCRP
contribution to the total transporter expression of 11 studied transporters in
the  liver  was  merely  1%  as  reported  by  Wang  et  al.  (2015)  and  even  lower
(0.34%) according to a meta-analysis of proteomics data from Caucaisians by
Burt et al. (2016). In contrast, the meta-analysis evaluated the contribution of
MRP2 and P-glycoprotein in the liver to be around 2% each (Burt et al., 2016).
Review of the literature
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In  the  intestine  and  colon,  the  absolute  protein  abundance  of  BCRP has
been measured to be roughly between 0.1 and 0.5 pmol/mg membrane protein
by Groer et al. (2013) and Drozdzik et al. (2014), whereas some studies report
values  around  2.5  pmol/mg  membrane  protein  (Harwood  et  al.,  2015;
Harwood  et  al.,  2016a;  Nakamura  et  al.,  2016).  This  more  than  five-fold
difference could be due to the applied analytical methods or the inherent
variability in samples. BCRP expression appears to decrease slightly along the
length of the intestine (Groer et al.,  2013; Drozdzik et al.,  2014; Harwood et
al., 2015), but this finding may be obscured by the small number of samples
analysed in the studies. BCRP tends to be expressed at similar or slightly lower
levels compared to the other intestinal drug efflux transporters, P-
glycoprotein and MRP2 (Groer et al., 2013; Drozdzik et al., 2014; Harwood et
al., 2016a; Nakamura et al., 2016). In the liver and kidney, the expression of
BCRP  is  lower  than  P-glycoprotein  and  MRP2  (Fallon  et  al.,  2016).  BCRP
expression in the liver showed approximately 3-fold interindividual
variability, which is less than in the intestine (Tucker et al., 2012; Prasad et al.,
2013). The average expression of BCRP in liver samples from 50 donors was
0.14 pmol/mg membrane protein and did not show any dependency on sex,
age or condition of the liver (fatty vs. non-fatty) (Prasad et al., 2013).
The closest human protein to BCRP, with approximately 30% sequence
identity, is ABCG1, the human homologue of the Drosophila White protein.
While  ABCG1  and  other  ABCG  family  transporters  are  mainly  involved  in
cholesterol  transport  (Velamakanni  et  al.,  2007),  the  role  of  BCRP  in
cholesterol transport is unclear. Cholesterol is, however, important for BCRP
function. In the cell membrane, BCRP is located in lipid rafts, which are areas
of the membrane that are enriched in cholesterol (Storch et al., 2007). BCRP
shows decreased activity after cholesterol depletion (Storch et al., 2007;
Telbisz  et  al.,  2007)  and  in Spodoptera frugiperda (Sf9)  insect  cell  based
preparations that have lower endogenous  membrane cholesterol  content than
mammalian cells (Pal et al., 2007; Telbisz et al., 2007). On the other hand, the
cholesterol-loading of BCRP-overexpressing Sf9 membrane vesicles
significantly increases the drug-stimulated ATPase activity and transport rate
of BCRP substrates (Pal et al., 2007; Telbisz et al., 2007).
BCRP is involved in the transport of endogenous compounds such as uric
acid (Matsuo et al., 2009; Woodward et al., 2009), and estrogen conjugates,
including estrone-3-sulphate (E1S)  (Imai  et  al.,  2003).  BCRP is  also  able  to
transport estradiol-17β-glucuronide (E217G), although in general, it tends to
favour  the  transport  of  sulphate  conjugates  (Chen  et  al.,  2003;  Imai  et  al.,
2003;  Suzuki  et  al.,  2003).  Based  on in vitro studies  in  Bcrp  or  BCRP
overexpressing cell lines and in vivo studies in mice, BCRP protects the body
against dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine  (PhIP)  (van  Herwaarden  et  al.,  2003;  Pavek  et  al.,  2005),
photosensitiser pheophorbide A and protoporphyrin IX (Jonker et al., 2002).
A variety of structurally unrelated drugs are transported by BCRP. Notably,
BCRP can confer resistance to chemotherapeutics including mitoxantrone
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(Doyle et al., 1998; Maliepaard et al., 1999), methotrexate (Chen et al., 2003),
tyrosine kinase inhibitors, such as gefitinib and erlotinib (Elkind et al., 2005;
Li et al., 2007), as well as topoisomerase I inhibitors topotecan and SN-38, a
metabolite of irinotecan (Maliepaard et al., 1999; Jonker et al., 2000; Jonker
et  al.,  2002;  Nagashima  et  al.,  2006).  On  the  other  hand,  P-glycoprotein
substrates  paclitaxel  and  vincristine  are  not  related  to  drug  resistance  in
BCRP-overexpressing cells (Doyle et al., 1998). BCRP substrates that are not
cancer drugs include, but are not limited to, cimetidine (Pavek et al.,  2005),
sulphasalazine (Zaher et al., 2006; Jani et al., 2009) and statins such as
rosuvastatin and atorvastatin (Kitamura et al., 2008; Keskitalo et al., 2009).
The structures of selected BCRP substrates are shown in Figure 1B.
In  addition  to  BCRP  substrates,  a  large  number  of  drugs  and  drug-like
compounds  have  been  shown  to  inhibit  BCRP  and  there  is  considerable
overlap in inhibitors especially between BCRP and P-glycoprotein (Matsson et
al., 2007; Matsson et al.,  2009). Standard BCRP inhibitors used in research
are  fumitremorgin  C  (FTC),  a  fungal  toxin,  (Rabindran  et  al.,  2000)  and
Ko143,  its  more  potent  and  less  toxic  derivative  (Allen  et  al.,  2002).  Other
inhibitors include steroid hormones and drugs (Imai et al., 2003; Pavek et al.,
2005; Dankers et al.,  2012), immunosuppressants (Gupta et al.,  2006), HIV
protease inhibitors (Gupta et al., 2004), and calcium channel blockers (Zhang
et  al.,  2005b),  as  well  as  many  natural  compounds,  especially  flavonoids
(Zhang et al., 2004; Tan et al., 2013).
The  binding  site  and  transport  mechanism  of  BCRP  are  poorly  defined,
because there is no available high-resolution crystal structure of the protein
(Gandhi & Morris, 2009). Based on the analysis of ATPase stimulation data of
39 compounds, Xu et al. (2015) proposed that BCRP binds its substrates in the
cytosolic  leaflet,  after  they  have  partitioned  into  the  lipid  bilayer.  A  similar
mechanism  was  suggested  by  Matsson  et  al.  (2007),  who  found  that
membrane partitioning and the presence of π-electron systems were
important  characteristics  of  BCRP  inhibitors  in  a  cell-based  assay.  The
presented pharmacophore, that includes a hydrogen bond acceptor, is also in
line with the proposed role of transmembrane helix hydrogen bond donors for
the extraction of ligands from the lipid bilayer by BCRP (Xu et al., 2015). The
specific residues that are involved in the interaction of BCRP with its ligands
are yet to be elucidated. However, studies on the spontaneous R482 variants
of BCRP found in cell lines indicate that this residue in transmembrane helix
3 is  important for the interaction of  substrates with BCRP. A change at  this
position to glycine or threonine abrupts the transport of methotrexate and
folic acid, but results in the ability to transport daunorubicin, rhodamine 123
and Lyso Tracker Green, which are not transported by wild type (WT) BCRP
(Chen et al., 2003; Robey et al., 2003).
Quantitative structure-activity relationship (QSAR) models and structure-
activity relationship analyses, that relate molecular properties to biological
activity,  have  been  made  mainly  for  BCRP  inhibitors  and  on  fairly  narrow
datasets of  related compound structures (Gandhi & Morris,  2009).  Many of
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these studies are not aimed at predicting drug-drug interactions, but at finding
potent and selective BCRP inhibitors to overcome multidrug resistance.
Therefore, the datasets typically contain analogues of know BCRP inhibitors
such as fumitremorgin, tariquidar, and flavonoids (Gandhi & Morris, 2009).
Although it is difficult to draw overall conclusions from the (Q)SAR studies, it
seems that lipophilicity, described by either water-lipid partitioning
coefficient LogP or LogD7.4, and the planarity of the molecule are important
features of BCRP inhibitors (Gandhi & Morris, 2009). Additionally,
aromaticity was identified alongside LogD7.4 as  a  determinant  of  BCRP
inhibition (Matsson et al., 2009).
2.1.1 PHARMACOGENETICS OF BCRP
Several hundred single-nucleotide polymorphisms (SNPs) or variants (SNVs)
have been identified in the ABCG2 gene (1000 Genomes Project Consortium,
2015). These include non-synonymous polymorphisms, which result in a
change of the coded amino acid, and could, therefore, affect protein structure
and function. The most common non-synonymous genetic variants of BCRP
are c.34G>A (rs2231137) and c.421C>A (rs2231142), which cause the amino
acid changes p.V12M and p.Q141K, respectively. The frequency of these
variants varies between populations of different ethnicity. The c.421C>A
variant  is  present  at  a  minor  allele  frequency  of  29% in  East  Asians,  9% in
Europeans, and only 1% in Africans (1000 Genomes Project Consortium,
2015).  In  the  Finnish  population,  the  c.421A  allele  is  reported  to  have  a
frequency of 9.5% (Keskitalo et al., 2009). A similar trend in frequency is seen
for c.34A allele, which is most prevalent in East Asians (33%), but only present
in 6% of Europeans and Africans (1000 Genomes Project Consortium, 2015).
Other variants occur at considerably lower frequency and are thus rarely
represented in clinical studies. Of note is that null alleles of ABCG2 define the
blood  group  phenotype  Jr(a-),  which  can  result  in  serious  transfusion
reactions (Saison et al., 2012; Zelinski et al., 2012).
The p.Q141K polymorphism appears to impair BCRP transport activity and
it seems to be a risk factor for hyperuricemia and gout due to the decreased
excretion of uric acid (Matsuo et al., 2009; Woodward et al., 2009). The risk
of  gout  is  also  increased  in  subjects  with  the  p.Q126X  variant,  a  nonsense
mutation  in  the  intracellular  region  of  BCRP  (Matsuo  et  al.,  2009).  The
observed  change  in  the  activity  of  the  p.Q141K variant  can  be  explained,  at
least partly, by the reduced expression of BCRP. A proteomics study on human
liver samples showed that patients harbouring the p.Q141K polymorphism had
significantly lower BCRP expression levels than those with WT BCRP (Prasad
et al., 2013). This is in line with findings from in vitro studies, which show that
the expression of p.Q141K is ≤ 50% of WT BCRP expression, probably due to
the proteasomal degradation of the variant (Kondo et al., 2004; Tamura et al.,
2006;  Tamura  et  al.,  2007b;  Urquhart  et  al.,  2008;  Furukawa et  al.,  2009;
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Skoglund et al., 2014). However, no change in expression related to genotype
was seen in human intestinal biopsy samples (Urquhart et al., 2008). Contrary
to the p.Q141K variant, p.V12M does not appear to affect expression levels in
vitro and it  has limited effects  on transport  activity  (Tamura et  al.,  2007a;
Yamasaki et al., 2008; Matsuo et al., 2009; Deppe et al., 2014; Skoglund et al.,
2014; Kim et al., 2015).
Due to its fairly high frequency, the p.Q141K variant has been the focus of
many  pharmacogenetics  studies,  which  have  mainly  concentrated  on  anti-
cancer agents and statins. These studies have been covered extensively in a
review  by  Mao  and  Unadkat  (2015).  Their  compilation  of  the  research
indicates increases of exposure up to 3.5-fold in the subjects with the p.Q141K
variant  compared  to  WT  subjects.  However,  the  consequences  of  the
polymorphism were not found to be significant in all  studies and appear to
depend on the drug, its dosing route as well as the genotype (heterozygous or
homozygous)  of  the  study  population  (Mao & Unadkat,  2015).  More  recent
reports suggest that bicalutamide, a prostate cancer drug, is influenced by the
p.Q141K polymorphism and homozygotes may experience a 60% increase in
exposure (Kim et al., 2015). Moreover, Bauer et al. (2016) reported an effect of
p.Q141K on [11C] tariquidar brain distribution in a positron emission
tomography (PET) study, but only in the presence of P-glycoprotein inhibition.
Information about the effects of polymorphisms is important, since
increased plasma concentrations and exposure may manifest as an increased
risk for side effects, as seen for gefinitib induced diarrhoea in patients with the
p.Q141K variant (Cusatis et al., 2006). For the low frequency variants, in vivo
data on their functional consequences is generally unavailable. In vitro data,
however, suggests that several naturally occurring BCRP polymorphisms
decrease either (cell surface) expression or transport activity, or both, of the
variant  proteins  (Kondo  et  al.,  2004;  Tamura  et  al.,  2007a;  Tamura  et  al.,
2007b;  Yoshioka  et  al.,  2007;  Kawahara  et  al.,  2010;  Deppe  et  al.,  2014;
Skoglund et al., 2014).
2.1.2 CLINICAL SIGNIFICANCE OF BCRP
The influence of  a  transporter on the overall  permeability  of  a  compound is
dependent not only on the affinity and transport rate of the transporter, but
also the passive permeability of the compound (Giacomini et al., 2010; Poirier
et al., 2014). Highly lipophilic and thus, highly permeable compounds are less
dependent on active mechanisms to cross cell membranes. On the other hand,
the  role  of  a  single  transporter  will  be  downplayed  if  several  parallel  active
routes exist. Moreover, when evaluating clinical significance, the effects of
altered  PK  must  always  be  evaluated  within  the  context  of  the  so  called
therapeutic  window of  the drug (Poirier  et  al.,  2014).  For some drugs,  even
large fluctuations in drug concentrations do not cause changes in efficacy or
Review of the literature
20
safety, but for others, such as P-glycoprotein substrate digoxin, even a slight
increase in concentrations can cause adverse effects.
In 2010, the International Transporter Consortium (ITC) highlighted
BCRP  as  one  of  the  important  transporters  to  be  considered  during  drug
development (Giacomini et al., 2010). BCRP interaction studies have since
been included in the drug-drug interaction (DDI) guidance documents of both
the  US  Food  and  Drug  Administration  (FDA)  and  the  European  Medicines
Agency (EMA)(European Medicines Agency, 2012; US Food and Drug
Administration, 2012). Drugs should be studied to determine whether they are
substrates of  BCRP, and thus possible victims of  DDIs,  or  whether they are
inhibitors, meaning that they could be perpetrators of DDIs. Substrate studies
may, however, be waived in the case of highly permeable and soluble drugs,
which are unlikely to be greatly influenced by active transport (Tweedie et al.,
2013). Despite the recognition of BCRP as significant factor in drug PK, clinical
data  on  BCRP-mediated  DDIs  is  rare  compared,  for  example,  to  the  data
available for P-glycoprotein, that includes over 60 documented DDIs where P-
glycoprotein  is  implicated  (Poirier  et  al.,  2014).  To  date,  the  strongest  data
supporting the clinical importance of BCRP on the PK of drugs comes from the
pharmacogenetics  studies  in  subjects  harbouring  the  p.Q141K  variant  of
BCRP.
Studies  in  Bcrp  knockout  (Bcrp1-/-)  mice  have  been  important  in
recognizing  the  potential  significance  of  BCRP  transport  on  drug  PK  and
disposition into protected tissue compartments such as the brain, placenta,
and testis (Vlaming et al., 2009). They have shown, for example, that Bcrp can
limit the brain entry of tyrosine kinase inhibitors imatinib and sorafenib, but
the  effects  of  Bcrp  at  the  blood-brain  barrier  are  generally  fairly  modest
(Agarwal et al. 2010, Kalvass et al. 2013). It should be kept in mind that data
from knockout animal models can be confounded by expressional changes of
other transporters and the interpretation of data may be difficult if the
disposition and elimation routes are very different in the preclinal species
compared  to  humans.  Knockout  models  also  serve  as  a  kind  of  ‘worst-case’
model for BCRP inhibition and can thus overpredict the magnitude of DDIs.
For  example,  studies  in Bcrp1-/- mice  show  a  6-fold  increase  in  the
bioavailability of oral topotecan compared to WT mice (Jonker et al., 2000).
In cancer patients, however, GF120918 increased oral topotecan
bioavailability  by  only  2.4  fold  (Kruijtzer  et  al.,  2002).  Exposure  to
sulphasalazine in Bcrp1-/- mice  was  111-fold  higher  compared  to  WT  mice
when dosed orally (Zaher et al., 2006), but the increase in oral sulphasalazine
AUC was less pronounced (8-fold) when Bcrp was inhibited with curcumin in
mice and smaller still (2.0 − 3.2 fold) in human volunteers (Kusuhara et al.,
2012). The data from the curcumin inhibition study in humans is similar to
changes  observed  in  clinical  studies  with  subjects  with  the  BCRP  p.Q141K
polymorphism,  which  showed  up  to  a  3.5  fold  increase  in  the  exposure  of
sulphasalazine (Urquhart et al., 2008; Yamasaki et al., 2008). In addition to
these drug interactions/knockout effects, it was recently reported that the
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investigational tyrosine kinase inhibitor fostamatinib, a BCRP inhibitor,
increased rosuvastatin exposure by almost 2-fold (Martin et al., 2016).
The  challenge  in  ascribing  the  observed  DDIs  to  BCRP  is  the  distinct
overlap  of  substrate  and  inhibitor  specificities  not  only  between  ABC
transporters, but also the influx transporters of the organic anion transporting
polypeptide (OATP) family as well as cytochrome P450 enzymes (Poirier et al.,
2014). For example, several clinical DDI studies performed with rosuvastatin
as the victim drug show a significant increase in peak plasma concentration or
exposure  when  co-administered  with  a  BCRP  inhibitor  (Mao  &  Unadkat,
2015).  However,  since  rosuvastatin  is  also  a  substrate  of  several  OATP
transporters (Kitamura et al., 2008), the inhibition of these transporters may
also contribute to the observed changes. The same applies for the interaction
between topotecan and GF120918 described by Kruijtzer et al. (2002);
although the contribution of P-glycoprotein to topotecan kinetics is considered
low, it cannot be ruled out as a component of the observed interaction.
The need for in vivo DDI studies to clarify the role of a new drug as a BCRP
inhibitor  can  be  evaluated  by  looking  at  the  ratio  of  expected  plasma  or
intestinal concentrations and an in vitro derived IC50 value, which is the
concentration required to inhibit 50% of transport. The ITC recommends an
in vivo DDI  study  to  be  conducted  if  this  ratio  is  above  0.1  for  plasma (i.e.
[I]1/IC5o ≥ 0.1)  and  10  for  intestinal  concentrations  (i.e.  [I]2/IC5o ≥ 10)
(Tweedie et  al.,  2013).  Optimal practices for the in vivo study are, however,
still debated. Recently, Lee et al. (2015) proposed sulphasalazine as a probe
substrate for BCRP-mediated intestinal DDIs and rosuvastatin for both
intestinal  and  hepatic  DDIs.  To  study  whether  a  new  drug  will  suffer  from
BCRP inhibition, curcumin and lapatinib are recommended as inhibitors (Lee
et al., 2015). The need for more than one substrate and inhibitor points to the
complexity of BCRP interactions due to its localization in different tissues as
well as the overlap in inhibitor specificity with other transporters. It should be
noted,  for  example,  that  the  inhibition  of  hepatic  BCRP  transport  may  not
result  in  altered  plasma  concentrations,  but  exposure  in  the  liver  could  be
evaluated by monitoring the cholesterol-lowering effects of rosuvastatin (Lee
et al., 2015).
2.2 MULTIDRUG RESISTANCE ASSOCIATED PROTEIN
2 (MRP2)
The multidrug resistance associated protein 2 (MRP2), previously also known
as  the  canalicular  multispecific  organic  anion  transporter  (cMOAT),  is
encoded by the ABCC2 gene.  This  protein,  composed  of  1545  amino  acids,
belongs  to  the  ABCC  family,  which  is  often  referred  to  as  the  multidrug
resistance  associated  protein  (MRP)  family,  due  to  their  presumed  role  in
resistance  to  cancer  treatment.  In  contrast  to  BCRP,  which  is  smaller  than
typical ABC transporters, MRP2 has altogether 17 transmembrane helices in
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three TMDs (Nies & Keppler, 2007)(Figure 2A). The five helices that make up
the so called TMD0 in the N-terminus are important for the trafficking of the
protein to its correct apical location in cells (Fernandez et al., 2002). MRP2,
like BCRP, is expressed at apical membranes in the intestine, liver, and kidney
(Sandusky et al., 2002). According to a proteomic analysis by Drozdzik et al.
(2014), the expression of MRP2 accounts for up to 10% and 25% of the total
transporter  abundance  of  clinically  relevant  multidrug  transporters  in  the
small  intestine  and  colon,  respectively.  A  similar  analysis  of  liver  samples
suggests that MRP2 contributes as much as 9% to the expression of quantified,
potentially clinically significant, transporters in the liver (Wang et al., 2015).
However,  based  on  a  meta-analysis  of  proteomic  studies,  MRP2  seems  to
contribute roughly 2% to hepatic drug transporters in Caucasians (Burt et al.,
2016).
In  the  liver,  MRP2  is  involved  in  the  biliary  excretion  of  bilirubin
conjugates.  It  was,  in  fact,  originally  cloned  from  rats  and  was  found  to  be
absent in two mutant strains of hyberbilirubinemic rats (Buchler et al., 1996).
In humans, a similar phenotype of conjugated hyperbilirubinemia is related to
the absence of MRP2 at the canalicular membrane in the liver (Kartenbeck et
al., 1996). This syndrome, called the Dubin-Johnson syndrome, can be caused
by several sequence variants of the ABCC2 gene that lead to a dysfunctional
MRP2 protein (Nies & Keppler, 2007). Despite jaundice and the pigmentation
of the liver, Dubin-Johnson syndrome appears benign (Dubin & Johnson,
1954).
Figure 2 (A) Membrane topology of MRP2 and (B) molecular structures of selected
substrates
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In addition to bilirubin conjugates, MRP2 translocates a variety of endogenous
and exogenous organic anions and anionic conjugates, mainly glucuronides
and glutathione conjugates (Nies & Keppler, 2007). The endogenous
substrates of MRP2 include leukotriene C4 (LTC4) and E217G (Cui et al., 1999).
MRP2  can  confer  resistance  to  chemotherapeutics  such  as  vincristine,
etoposide,  doxorubicin,  and  epirubicin  (Cui  et  al.,  1999)  as  well  as
methotrexate (Hulot et al., 2005) and irinotecan (Chu et al., 1997). In addition,
MRP2 contributes to the intestinal and biliary efflux of other drugs, such as
statins (Matsushima et al., 2005). The structures of selected MRP2 substrates
are presented in Figure 2B.
MRP2  is  inhibited  by  many  drugs,  for  example  benzbromarone,
cyclosporine  A,  lansoprazole,  and  lopinavir  (Pedersen  et  al.,  2008).  The
leukotriene D4 receptor antagonist MK-571 is a typically used in vitro MRP2
inhibitor, which was originally considered MRP-specific, but has since been
shown to inhibit other ABC transporters as well (Wang et al., 2008; Matsson
et al., 2009). As is the case for many transporters, there is a lack of specific
MRP2  inhibitors  available  (Hillgren  et  al.,  2013).  SAR  studies  on  MRP2
suggest  that  lipophilicity,  aromaticity,  and hydrogen bonding are important
features  for  MRP2  interaction  (Pedersen  et  al.,  2008;  Zhang  et  al.,  2009;
Wissel  et  al.,  2015;  Wissel  et  al.,  2017).  However,  substrates  and  specific
inhibitors  of  MPR2  tend  on  average  to  be  less  lipophilic  than  BCRP  or  P-
glycoprotein inhibitors and substrates (Matsson et al., 2009). Anionic charge
seems to be more important for MRP2 substrate transport and stimulation
than for inhibition (Pedersen et al., 2008). Although the presence of a negative
charge may improve inhibitory activity, it is not a requirement for inhibition
(Wissel et al., 2017).
MRP2 is characterized by higher selectivity for interaction than BCRP and
P-glycoprotein  as  highlighted  by  Matsson  et  al.  (2009).  Out  of  122  studied
compounds,  26  (21%)  inhibited  MRP2,  whereas  the  number  was  almost
double for P-glycoprotein and BCRP. Notably, 73% of MRP2 inhibitors were
also inhibitors of either P-glycoprotein or BCRP or both. Furthermore, MRP2
was  much  more  selective  than  its  family  member  MRP1  (ABCC1)  in  a
structure-activity analysis of flavonoids; out of the 29 studied compounds,
most inhibited MRP1, but only two compounds inhibited MRP2 (van Zanden
et al., 2005).
The transport of E217G exhibits sigmoidal kinetics in MRP2 vesicles, which
suggests that MRP2 has at least two ligand binding sites, one of which may be
involved  directly  in  transport  and  the  other  in  its  modulation  (Bodo  et  al.,
2003; Zelcer et al., 2003). The presence of an allosteric binding site makes the
inhibitory  and  stimulatory  effects  of  compounds  on  MRP2  complex  and
substrate-dependent (Zelcer et al., 2003; Kidron et al., 2012). For example,
diclofenac and E1S stimulate MRP2-mediated E217G transport, but inhibit the
transport of LTC4 and the fluorescent probe 5(6)-carboxy-2,7-
dichlorofluorescein (CDCF) (Kidron et al., 2012).
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There are few in vivo studies that link MRP2 function to altered
pharmacokinetics  of  drugs  in  humans.  In  a  case-study,  Hulot  et  al.  (2005)
reported that a loss-of-function MRP2 variant (R412G) was linked to
methotrexate  overdose  and  nephrotoxicity.  Additionally,  a  SNP  in  the  5’-
flanking  region  of  MRP2  is  suggested  to  be  associated  with  a  decrease  in
irinotecan-induced diarrhoea, but only in patients where the risk was already
decreased  by  a  particular  UGT1A1  genotype  (de  Jong  et  al.,  2007).
Furthermore, a synonymous polymorphism (T482T) appears to decrease
pravastatin exposure, possibly due to an increase in expression levels of MRP2
(Niemi et al., 2006).
To  date,  there  are  no  clear  clinical  examples  of  MRP2-mediated  DDIs
(Hillgren  et  al.,  2013),  although  it  has  been  proposed  that  the  induction  of
intestinal MRP2 expression by rifampicin could be one factor in the DDIs of
rifampicin with morphine and propafenone (Fromm et al., 2000). One
explanation for the lower number of in vitro identified interactions compared
to  other  ABC  drug  transporters  could  be  the  preference  of  MRP2  for
conjugated metabolites. Early in vitro interaction studies typically focus on the
parent compounds and not on the metabolites that may be formed in vivo. It
is, however, possible that the inhibition of hepatic MRP2 could lead to toxicity
caused by the intracellular accumulation of MRP2 substrates. The inhibition
of MRP2 is therefore recommended to be studied if clinical or preclinical data
point to drug−induced conjugated hyperbilirubinemia (Hillgren et al., 2013).
2.3 IN VITRO METHODS AND EXTRAPOLATION TO IN
VIVO
The interactions of drugs with ABC transporters can be studied with several in
vitro methods. The rationale for choosing a certain method should be based
on the properties of the compound being evaluated as well as the research
question (Brouwer et  al.,  2013;  Zamek-Gliszczynski  et  al.,  2013).  Since each
method has its own limitations, the complementary use of different methods
is often beneficial for elucidating transporter interactions (Glavinas et al.,
2008). The in vitro methods can be categorized roughly into cell-based and
vesicle-based  methods,  and  they  can  be  applied  to  either  study  whether  a
compound is  a  substrate  of  a  transporter  or  whether  it  is  an  inhibitor.  The
principles and main properties of the in vitro methods typically used to study
BCRP and MRP2 are described below. Emphasis is given to techniques, from
which the output data can be used to extrapolate in vitro findings to in vivo
situations.
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2.3.1 IN VITRO METHODS FOR EVALUATING EFFLUX AND
INHIBITION
The permeability of a drug across a polarized cell membrane can be studied in
confluent monolayers grown on permeable membrane supports. Cell lines that
are commonly used include the human colorectal adenocarcinoma cell line
Caco-2, which is recommended to be used as an intestinal model, as well as
kidney derived cell lines from pig (LLC-PK1) and dog (Madin-Darby canine
kidney,  MDCK)  (European  Medicines  Agency,  2012;  US  Food  and  Drug
Administration, 2012; Brouwer et al., 2013). These kidney cell lines form tight
monolayers and they can be transfected with the cDNA of the transporter of
interest (Brouwer et al., 2013). To evaluate whether a compound is a substrate
for a certain transporter, in a typical setting, the apparent permeability (Papp)
of a compound in the apical to basolateral (A-B) and in the basolateral to apical
(B-A)  directions  is  determined  (Figure  3).  With  this  information,  the  efflux
ratio (ER) can be calculated:
(1) 𝐸𝑅 = ௉ೌ೛೛ ಳషಲ௉ೌ೛೛ ಲషಳ
The ER is a measure of how much influence a transporter has on overall drug
permeability. Efflux transporters on the apical membrane hinder the A-B
permeability, but enhance permeation in the B-A direction. Compounds with
ER  values  above  two  are  usually  considered  to  be  transporter  substrates
(Brouwer et al., 2013). The ER in control cells should be around one, since the
permeability  is  expected  to  be  equal  in  both  directions  in  the  absence  of
transporters. The ER ratio is influenced not only by active transport, but also
passive diffusion across the cell monolayer. Therefore, the monolayer integrity
and leakiness should be carefully monitored using passive permeability
markers, for example mannitol and by measuring transepithelial resistance
(TEER) (Hubatsch et al., 2007).
Using the monolayer assay, the effects of efflux transporters may be
underestimated for low permeability compounds that rely on active influx to
enter cells in vivo.  For  these  compounds,  it  may  be  beneficial  to  use  an
organotypic cell line, such as Caco-2, instead of an overexpression system, or
to perform studies in double-transfected cell lines. For example, the
combination  of  hepatic  influx  transporter  OATP1B1  with  MRP2 in  MDCKII
cells  was  needed  to  identify  the  contribution  of  MRP2  to  E217G transport
(Matsushima et al., 2005). Without the uptake transporter, no directional
permeability could be observed. Appropriate controls and non-transfected cell
lines should always be used to rule out any interference of endogenous
transporters expressed by the cell line. It should, however, be noted that the
endogenous transporter expression may vary between transfected cells and
the  parent  cell  line  (Kuteykin-Teplyakov  et  al.,  2010).  For  organotypic  cell
lines,  the  use  of  inhibitors  is  usually  required  to  clarify  the  role  of  a  single
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transporter.  This  approach  is,  however,  complicated  by  the  lack  of  specific
transporter inhibitors as described earlier.
Figure 3 Scheme of the transcellular transport assay. A monolayer of cells is grown on a
permeable membrane support and the permeability of a compound across the cell membrane is
measured. Measurements are typically performed in both the apical to basolateral (A-B) and the
basolateral to apical (B-A) directions. The presence of apical efflux transporters (dark grey square),
such as BCRP or MRP2, will increase permeability in the B-A direction and decrease the apparent
A-B permeability of substrate drugs.
Cell  monolayers  can  also  be  used  to  study  the  kinetics  of  transport  and
calculate the maximum velocity of transport (Vmax) and  the  Km, which
describes affinity and corresponds to the concentration required to reach 50%
of Vmax. However, these calculations require the application of compartmental
models to the data to derive reliable and system-independent parameter
values (Tachibana et  al.,  2010; Harwood et  al.,  2013;  Zamek-Gliszczynski  et
al.,  2013).  Inhibition  in  cell  monolayers  can  be  studied  either  at  a  single
concentration or over a concentration range to determine the IC 50 value or the
inhibition constant Ki. Whereas the IC50 is related to specific assay conditions,
such  as  substrate  concentration,  the  Ki is  a  more  robust  parameter
(Burlingham & Widlanski, 2003). However, the workload required to
determine the Ki value is significantly higher than that required for the IC50,
which is why the latter is often favoured. Several calculation methods can be
applied to estimate IC50 values and it  should be noted that  they can lead to
slightly different results (Bentz et al.,  2013). This may have an impact when
comparing the results to cut-off IC50 and expected in vivo inhibitor
concentration ratios set by the regulatory authorities. Although kinetic
parameters and IC50 values can be measured with the monolayer experiments,
the drawback of the system, especially for these types of experiments, is that
they are fairly labour intensive and costly. Experiments are usually performed
manually in a 12- or 24-well plate format, which results in low throughput and
limits the amount of different concentrations to be tested, for example.
Automation may serve as a way to circumvent this disadvantage (Larson et al.,
2012), especially in an industrial setting.
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Besides transcellular permeability studies, inhibition may also be studied
by  measuring  the  accumulation  of  a  probe  substrate,  typically  a  fluorescent
compound, in cells overexpressing the transporter of interest (Hegedus et al.,
2009).  The  inhibition  of  efflux  is  seen  as  an  increase  in  the  intracellular
accumulation of the probe compared to the control with probe only and based
on this data, IC50 values can be calculated. Although it is possible, substrates
are rarely studied with these accumulation studies (Hegedus et al., 2009). On
the other hand, sandwich-cultured hepatocytes (SCH) are a specialized system
to study hepatic processes in detail. In this system, primary hepatocytes grown
between two collagen layers polarize and start to display canalicular networks
typical to the liver (Swift et al., 2010). Because primary hepatocytes are used,
both  uptake  and  efflux  transporters,  as  well  as  metabolic  enzymes,  are
expressed in the system. Transport studies are performed in the presence and
absence of calcium ions. The removal of Ca2+ ions leads to the opening of the
tight junctions of the bile canaliculi. The resulting data can be used to calculate
a biliary excretion index, apparent biliary clearance or intrinsic biliary
clearance,  of  which  the  latter  parameter  can  be  further  utilised  in
pharmacokinetic models (Brouwer et al., 2013).
In addition to whole cells, the transport activity of ABC transporters can be
evaluated in inside-out oriented membrane vesicles that are formed when the
cell membrane is extracted (Glavinas et al., 2008). Vesicles can be produced
in principle from any cell types expressing the transporter of interest including
tissue preparations. Commonly used transporter-transfected cell lines include
human embryonic kidney (HEK293) cells and Chinese hamster ovary (CHO)
cells as well as Spodoptera frugiperda derived insect cells (Sf9, Sf21, or High-
five) (Glavinas et al., 2008; Brouwer et al., 2013). Transport proteins can also
be isolated,  purified,  and reconstituted into proteoliposomes to enable high
control  over  the  membrane  composition  and  ensure  the  absence  of
endogenous transport (Glavinas et al., 2008).
In  the  inside-out  vesicles,  efflux  transporters,  such  as  BCRP and MRP2,
pump substrates into, rather than out of the vesicles in the presence of ATP.
Passive permeability and unspecific binding to the vesicles is accounted for by
performing  assays  in  the  absence  of  ATP  and  subtracting  this  value  from
transport observed with ATP. The possible presence of endogenous transport
should be evaluated in vesicles prepared from parent cell lines. A schematic
illustration of the vesicular transport (VT) assay is shown for BCRP in Figure
4A. The amount of substrate accumulated into the vesicle can be determined
using fluorescence measurement, mass spectrometry, or scintillation counting
depending  on  the  substrate.  False  negative  results  may  be  obtained  for
compounds with high passive permeability that can diffuse out of the vesicles
or that produce a high background signal from nonspecific binding (Brouwer
et al., 2013; Tweedie et al., 2013). On the other hand, the VT assay is especially
suitable  for  studying  low  permeability  compounds,  such  as  the  hydrophilic
conjugates that are substrates of MRP2 (Glavinas et al., 2008; Hillgren et al.,
2013). The assay benefits from higher throughput than cell-based assays as it
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is easily performed in a 96-well plate format, and vesicles can be prepared in
large batches and preserved at – 80 °C. Michaelis-Menten type enzyme kinetic
calculations can directly be applied to the data, because the test compound has
direct  access  to  the  intracellular  domains  of  the  transporter  (Zamek-
Gliszczynski et al., 2013). The compound concentration in assay buffer is thus
a surrogate for the intracellular concentration.
Figure 4 Scheme of the vesicular transport assay for BCRP. In inverted membrane vesicles
BCRP transports its probe substrate into the vesicles (A). The amount of accumulated probe can
be measured. In the indirect application of the assay, the effect of test compounds on BCRP
transport activity can be evaluated (B). The effect of an inhibitor is seen as a reduction in uptake.
The inhibition or stimulation of transport by a compound can be studied using
an indirect application of the assay (Figure 4B). A probe substrate is incubated
in the presence and absence (control) of test compound. A decrease in probe
accumulation indicates inhibition, whereas stimulation results in an increased
amount of accumulated substrate. The requirement for inhibition assays is a
suitable probe compound that shows active high transport  compared to the
background.  This  can  be  a  problem  for  some  transporters,  for  example  P-
glycoprotein, that favour hydrophobic compounds as substrates. For BCRP
and MRP2, however, several suitable probes exist including methotrexate, E1S,
and Lucifer yellow for BCRP and E217G, LTC4 and CDCF for MRP2 (Heredi-
Szabo et al., 2008; Hegedus et al., 2009; Brouwer et al., 2013). A drawback of
the  vesicle  assay  is  that  it  is  rarely  possible  to  use  the  victim  drugs  of  the
potential DDIs as probe substrates, although this would be preferred due to
the possible substrate-dependency of inhibition (Tweedie et al., 2013).
Examples of  substrates and inhibitors that  may be used in whole cell-based
and vesicle-based studies are compiled in Table 1 and Table 2.
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Table 1 Examples of in vitro BCRP and MRP2 substrates.
Compound Km (μM) ER Test system Ref.
BCRP
E1S
7.4 - Sf9-BCRP vesicles Elsby et al.2011
16.6 - BCRP-P388 vesicles Suzuki et al.2003
- 4.5 MDCKII-BCRP cells Xia et al.2007
Methotrexate 681 - MCF7/MX vesicles
Volk and
Schneider
2003
Prazosin - 4.5 MDCKII-BCRP cells Poirier et al.2014
Rosuvastatin
2.02 & 60.9a - HEK-BCRP vesicles Kitamura etal. 2008
10.8 & 307a - BCRP vesicles Huang et al.2006
- § 5 MDCKII-BCRP cells Deng et al.2008
Sulphasalazine
0.7 - BCRP vesicles Jani et al.2009
- § 19b Caco-2 cells
Dahan and
Amidon 2009
MRP2
CDCF 12.3 - Sf9-MRP2 vesicles Heredi-Szaboet al. 2008
E217G
120 - Sf9-MRP2 vesicles Zelcer et al.2003
99 - HEK-MRP2 vesicles Elsby et al.2011
Methotrexate
- § 2-4 MDCK-MRP2 cells Jia et al. 2016
480 - MDCKII-MRP2vesicles
El-Sheikh et
al. 2006
Vinblastine 137 36 MDCK-MRP2 cells Tang et al.2002
a Values for high and low affinity binding sites
b Efflux partially mediated by MRP2
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Table 2 Examples of in vitro BCRP and MRP2 inhibitors.
Compound IC50 or Ki(μM)
Test system
(probe) Ref.
BCRP
Cyclosporin A
6.7 BCRP vesicles (E1S) Xia et al. 2007
< 50 μM MDCKII-BCRP cells(E1S)
Xia et al. 2007
Ko143
0.013 BCRP vesicles (E1S) Xia et al. 2007
0.026 Sf9-BCRP vesicles(methotrexate) Tan et al. 2013
0.01 MDCKII-BCRP cells
(pheophorbide A)
Weiss et al. 2007
Sulphasalazine 0.74
Sf9-BCRP vesicles
(E1S)
Elsby et al. 2011
MRP2
Benzbromarone
1.2 MDCK-ABCC2vesicles (CDCF)
Colombo et al.
2013
36 Sf9-MRP2vesicles (E217G)
Elsby et al. 2011
4.4 Sf9-MRP2 vesicles(CDCF)
Heredi-Szabo et al.
2008
Cyclosporin A
45.3 MDCKII-ABCC2
vesicles (CCK-8)
Letschert et al.
2005
21
HEK-MRP2 vesicles
(monoglucuronosyl
bilirubin)
Kamisako et al.
1999
8.11 MDCK-MRP2 cells(vinblastine) Tang et al. 2002
MK-571
10 Sf9-MRP2 vesicles(E217G)
Pedersen et al.
2008
7.6 MDCK-ABCC2 cells(CDCF)
Colombo et al.
2012
28 Sf9-MRP2 vesicles
(E217G)
Elsby et al. 2011
4.1
Sf9-MRP2 vesicles
(CDCF)
Heredi-Szabo et al.
2008
26.4 MDCK-MRP2 cells(vinblastine) Tang et al. 2002
Probenecid a
580 Sf9-MRP2 vesicles(CDCF)
Heredi-Szabo et al.
2008
2300 Sf9-MRP2 vesicles(LTC4)
Heredi-Szabo et al.
2008
a Stimulation of MRP2-mediated E217G transport also observed (Zelcer et al. 2003).
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2.3.2 UTILISATION OF IN VITRO DATA IN MODELLING
Although in vitro data  such  as  the  ER  and  IC50 values  can  be  used  by
themselves,  for  example  to  prioritise  compounds  for  further  stages  of  drug
development, the clinical significance of these interactions is difficult to
understand based on the in vitro kinetic or inhibition data alone (Brouwer et
al., 2013). The incorporation of in vitro derived data in mechanistic,
physiologically-based pharmacokinetic (PBPK) models can serve as a ‘bottom
up’  approach  to  understand  the  contributions  of  specific  processes  in
complicated systems (Rowland et al., 2011; Zhao et al., 2011). It also enables
the generation of dynamic time-course data instead of static values (Rowland
et al., 2011). Additionally, in vitro data can be used to refine covariate models
generated from in vivo data  using  the  classical  ‘top  down’  approach  to
modelling  (Jamei  et  al.,  2009).  The  complexity  of in silico (PBPK) models
should  always  be  based  on  the  question  that  the  model  is  built  to  answer.
Usually, the simplest model that can answer the proposed question is the most
suitable  choice.  In  principle,  there  is  no  limit  for  detail  in  PBPK  model
structure, but it quickly becomes limited by the vast amount of data required
for the detailed description of biological events.
In  PBPK  modelling,  the  body  is  represented  as  distinct  tissue
compartments that are connected to each other by blood flow. Depending on
the complexity and purpose of the model, tissue compartments may be divided
into subcompartments or lumped together. The key idea in PBPK modelling is
the separation of physiological data, the so-called system-related parameters,
and drug-related parameters from each other in the model (Jamei et al., 2009;
Rowland  et  al.,  2011).  The  systems-related  data  includes,  for  example,  the
volumes  and  weights  of  organs  as  well  as  blood  flow and  the  abundance  of
metabolic enzymes and transporters in these organs. The drug-related
parameters  include  physicochemical  properties  such  lipophilicity  and
ionisation, which are important for predicting distribution into tissues,
permeability properties, and metabolic and transporter-mediated clearances.
Additionally, interindividual variability and population differences can be
included by combining demographic data and variability to the physiological
parameters. This means that instead of simulating PK events in the average
man,  simulations  can  be  performed with  virtual  patients  that  represent  the
extremes of the likely patient populations (Rowland et al., 2011).
An integrated part of mechanistic PBPK modelling, is the in vitro – in vivo
extrapolation  (IVIVE)  of  metabolic  and  transporter  data.  There  are  several
basic steps in the IVIVE of transport data (Harwood et al., 2013). First, robust
data  must  be  available  to  describe  the  passive  permeability,  as  well  as  the
kinetic transport parameters, Km and Vmax, of the drug to be modelled. Second,
the Vmax value should be scaled. Vmax is an inherently system-based parameter
which is dependent on the expression level of the transporter in the system.
Thus,  appropriate  scaling  procedures  must  be  applied  to  account  for  the
difference in expression levels in vitro and in vivo. The importance of taking
expression levels into account during IVIVE was recently demonstrated by
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Olander  et  al.  (2016).  In  their  Caco-2  cell  permeability  study,  the  influx
transporter OATP2B1 contributed roughly 60% to pitavastatin uptake, but
when human intestinal  proteomic  data  was  used  to  scale  the  transport,  the
contribution of OATP2B1 was only 5%.Without the scaling, the in vitro data
would have resulted in a gross overestimation of the contribution of OATP2B1
to pitavastatin transport in vivo.
The evaluation of transporter expression has previously relied mainly on
mRNA  data,  which  sometimes  shows  low  correlation  with  actual  protein
expression (Vogel & Marcotte, 2012). Immunoblotting, can also be used, but
it  is  more  a  qualitative  than  a  quantitative  method.  Therefore,  the
advancement of mass spectrometric methods for protein quantification and
the increasing amount of data on transporter abundance in human tissues are
key factors for improving the quantitative IVIVE of transporters (Harwood et
al.,  2013).  For  example,  Harwood  et  al.  (2016c)  demonstrated  that  BCRP
protein abundance was better  correlated with the observed transport  of  E1S
than was mRNA expression.
Proteomic analysis is not without its challenges, however. Different
procedures  in  plasma  membrane  extraction  and  purification,  as  well  as
peptide  selection,  can  result  in  inter-laboratory  differences  as  shown,  for
example, by Harwood et al. (2016b). In a comparison of scaling between Caco-
2  and  intestinal  samples,  they  found  no  significant  difference  in  relative
expression for P-glycoprotein between two laboratories, but a 2-fold difference
was  observed  for  BCRP.  Although  the  difference  in  this  case  was  fairly
moderate, combining proteomic data from different sources might lead to
inaccurate  conclusions  due  to  this  variability.  Recently,  Vrana  et  al.  (2017)
published a paper which describes the generation of a database of methods for
the targeted proteomic quantitation of 284 proteins related to
pharmacokinetic processes. Efforts like this are likely to facilitate the
acquisition of high-quality proteomic data for PBPK modelling.
An assumption of proteomic data used to scale transport activity, is that all
of the detected protein is active. For vesicles, this assumption must be refined
by correcting the protein abundance with the proportion of vesicles that is in
the active, inverted conformation (Harwood et al., 2013; Vildhede et al., 2016).
Additionally,  it  should be kept in mind that in vitro derived parameters are
dependent  on  assay  conditions  and  calculation  methods.  Even  a  factor  that
may  seem  minor,  such  as  shaking,  can  have  a  clear  effect  on  the  observed
passive permeability of high permeability compounds (Artursson & Karlsson,
1991). Therefore, rigorous validation and optimisation of best practices are
required to provide robust estimates for in silico modelling.  Due  to  the
complexity of whole-body PBPK systems, the extrapolation principles
described above have been used for in vitro – in vitro extrapolation as a proof
of concept. Recently, Vildhede et al. (2016) combined efflux transporter data
generated  in  VT  assays  with  uptake  and  passive  diffusion  data  from
accumulation studies to model the kinetics of pitavastatin in sandwich-
cultured human hepatocytes. Transporter expression data from each system
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was used to scale parameters to the hepatocytes. Out of the nine transporters
studied, the simulations identified BCRP as the main transporter mediating
canalicular efflux and OATP1B1 as the main uptake transporter of pitavastatin.
In this way, the bottom-up in vitro simulation model presented by Vildhede et
al. (2016) was able to provide information about the relative contribution of
the different transporters in hepatocytes and increase confidence in the
bottom-up approach.
It should be noted that, in addition to permeability and transport related
parameters, models often require a parameter to describe intracellular
binding. Unbound intracellular concentrations may be of interest, because
many drug targets reside inside the cell and therefore this concentration is the
driving force for the pharmacological or toxicological effects. For example, the
IC50 concentrations  from  vesicle  studies  should  be  related  to  the  unbound
intracellular concentrations in PBPK models and therefore intracellular
binding must be accounted for. Equilibrium dialysis of the test compound with
cell  lysates  has  been  proposed  as  a  relatively  simple  way  of  measuring  the
binding  to  cellular  components  (Mateus  et  al.,  2013).  Although  it  has  its
limitation of disrupting cellular organelle integrity, this technique may prove
useful for estimating intracellular binding.
An  advantage  of  PBPK  models  is  that  they  allow  us  to  simulate
concentrations in tissues that cannot be accessed in humans, such as the liver.
This is useful, because hepatic intracellular concentrations are important in
understanding  drug-induced  liver  toxicity  (Chu  et  al.,  2013).  Moreover,
distribution  into  tissues  such  as  the  brain  cannot  be  resolved  from  plasma
concentration data. The challenge with the validation of detailed PBPK models
is  the  obvious  lack  of  clinical  data  on  tissue  concentrations.  Although  PET
studies are emerging as tool for studying the tissue distribution of transporter
substrates (Kusuhara, 2013), preclinical animal models are still an important
stepping stone toward better predictive models. The benefit of PBPK
modelling  is  that  it  can  take  into  account  the  physiological  differences  of
preclinical animals and humans. Proteomic data that describes interspecies
variability in transporter expression may help to explain observed differences
in PK between species (Wang et al., 2015; Fallon et al., 2016) and serve as a
link between preclinical species and clinical observations. For instance, cross-
species differences in BCRP expression levels have been found, with BCRP
expression in the human liver being almost 10-fold lower than in dogs and the
expression in the human kidney 50-fold lower than in rats (Fallon et al., 2016).
This magnitude of variability can be expected to influence the importance of
these routes in the elimination of BCRP substrate drugs and can be taken into
consideration in PBPK modelling. Possible species differences in substrate and
inhibitor specificity can be incorporated based on in vitro data. However,
according  to  Bakhsheshian  et  al.  (2013),  BCRP  substrate  and  inhibitor
specificities  seem to  be  similar  at  least  between  human and  mouse,  but  are
more variable for MRP2 (Zimmermann et al., 2008).
Aims of the study
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3 AIMS OF THE STUDY
The general aim of this Ph.D. thesis was to understand which compounds are
liable  to  interact  with  BCRP  and  how  BCRP  function  and  expression  can
change with genetic variation. How one experimental factor (the inclusion of
bovine serum albumin) could affect the observed transport in an established
assay system was also investigated. Natural and natural-like compounds, as
well  as  food  additives,  were  used  in  the  studies,  since  information  on  these
interactions is interesting in itself for identifying food-drug interactions. The
results  obtained  for  BCRP  were  compared  with  MRP2  results,  to  better
understand differences and similarities between these two ABC transporters.
The specific aims of the thesis were:
1. To study the effect of bovine serum albumin on the measured transport
kinetics of BCRP and MRP2 in the vesicular transport (VT) assay (I).
2. To  study  and  compare  the  inhibition  of  BCRP  and  MRP2  by  natural
compounds and their derivatives, and by selected food preservatives,
colorants and sweeteners (II, IV).
3. To identify important molecular properties of BCRP inhibitors (II).
4. To evaluate the effects of naturally occurring, transmembrane domain
single-nucleotide polymorphisms on the expression and the function of
BCRP (III).
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4 MATERIALS AND METHODS
4.1 MATERIALS
The key reagents and materials used in the studies are listed in Table 3. The
human ABCC2 (MRP2) and ABCG2 (BCRP) cDNAs were kindly provided by
Dr.  Piet  Borst  (Netherlands  Cancer  Institute,  the  Netherlands)  and  Dr.
Douglas  Ross  (University  of  Maryland  School  of  Medicine,  MD,  USA),
respectively. The in-house library used in publication II, contains 124 natural
compounds and natural compound dervatives from various commercial
sources.  The  major  compound  subgroups  in  the  library  are  flavonoids,
coumarins, and benzoic acid derivatives. In publication IV, the studied food
additives were selected from the list of food additives permitted for use in the
European Union and were obtained from Sigma-Aldrich (USA).
Table 3 Key reagents and materials used in the studies
Reagent/material Use Supplier Publication
Lucifer yellow CH dipotassium
salt (LY)
BCRP probe
Sigma-Aldrich
(USA)
I-IV
Estrone-3-sulphate (E1S) BCRP probe
Sigma-Aldrich
(USA)
III
3H-E1S (54 Ci/mmol) BCRP probe
Perkin Elmer
(USA)
III
5(6)-carboxy-2’,7’-
dichlorofluorescein (CDCF)
MRP2 probe
Sigma-Aldrich
(USA)
I,II,IV
Estradiol-17ȕ-glucuronide
(E217G)
MRP2 probe
Sigma-Aldrich
(USA)
I
Randomly methylated ȕ-
cyclodextrin cholesterol
(Cholesterol-RAMEB) complex
Cholesterol-loading of
BCRP vesicles
Cyclolab Ltd
(Hungary)
I-IV
Bio-Rad protein assay dye
Protein concentration
measurement
Bio-Rad (USA) I-IV
Essentially fatty acid free
bovine serum album
Studies on albumin
effects
Sigma-Aldrich
(USA)
I
Sf9 (Spodoptera frugiperda) cell
line
Expression of BCRP
and MRP2
ATCC (USA) I-IV
HyClone SfX insect cell medium Sf9 cell culture
ThermoFisher
Scientific (USA)
I-IV
Foetal bovine serum
Sf9 and HEK293 cell
culture
Gibco (USA) I-IV
HEK293 cell line (CRL-1573) Expression of BCRP ATCC (USA) III
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Reagent/material Use Supplier Publication
Dulbecco’s Modified Eagle
Medium (DMEM) (#32430)
HEK293 cell culture Gibco (USA) III
Bac-to-bac protocol
Generation of
recombinant baculovirus
Invitrogen (USA) I-IV
Cellfectin II reagent Sf9 cell transfection Invitrogen (USA) III
Q5 site-directed mutagenesis
kit
Incorporation of SNVs
New England
Biolabs (USA)
III
Gateway LR clonase II enzyme
mix
Gateway cloning
ThermoFisher
Scientific (USA)
III
10 % Mini-PROTEAN TGX
Stain-Free gel
SDS-Page Bio-Rad (USA) III
Anti-BCRP/ABCG2 antibody
BXP-21 (ab3380)
Western blot,
immunofluorescence
Abcam (UK) III
Goat Anti-Mouse IgG Antibody,
(H+L) HRP conjugate (AP308P)
Western blot Millipore (USA) III
Goat anti-Mouse IgG (H+L)-
Alexa Fluor 488 Antibody (A-
11001)
Immunofluorescence
ThermoFisher
Scientific (USA)
III
Amersham ECL Prime Western
blotting detection reagent
Western blot detection
GE Healthcare
(UK)
III
4.2 METHODS
4.2.1 EXPRESSION OF BCRP AND MRP2 TRANSPORT PROTEINS
Human MRP2 cDNA was subcloned from pGEM3-MRP2 into the pFastBac1
vector using BamHI/HindIII sites. BCRP cDNA was subcloned from pcDNA3-
BCRP into the BamHI/XhoI sites of the pFastBac1 plasmid. The QuikChange
Lightning Site-directed mutagenesis kit was used to convert the BCRP cDNA
to the WT BCRP (Uniprot Q9UNQ0). The pENTR221-hBCRP was constructed
as described in Dankers et al. (2012).
BCRP  and  MRP2  were  expressed  in  Sf9  (Spodoptera frugiperda) insect
cells (I-IV) and in human embryonic kidney 293 (HEK293) cells (III) using the
Bac-to-bac baculovirus expression system. A baculovirus containing the
enhanced yellow fluorescent protein (eYFP) gene and an empty bacmid served
as controls for the HEK293 and Sf9 systems, respectively.
Sf9 cells were cultured as a suspension at 27°C in HyClone SfX insect cell
culture medium supplemented with 5% FBS. HEK293 cells were grown as an
adherent culture in high glucose Dulbecco’s Modified Eagle Medium (DMEM)
(Gibco #32430) with 10 % FBS at 37°C, 5% CO2. Cells were harvested 55 – 72
h after  the addition of  baculovirus by centrifugation at  1000 g,  10 min (Sf9
cells) or 3000 g 15 min (HEK293 cells) at 4°C.
37
4.2.2 SITE-DIRECTED MUTAGENESIS
The BCRP variants (III) were produced using the Q5 site-directed mutagenesis
kit. Non-synonymous SNVs were incorporated into the ABCG2 gene in either
the  pFastBac1-BCRP  or  the  pENTR221-hBCRP  plasmids.  The  1582  G>A
(A528T) variant was made using Q5 polymerase with overlapping primers and
template DNA was degraded using the DpnI enzyme. All  resulting plasmids
were sequenced for the whole ABCG2 gene to verify the presence of the SNVs
using the GATC Biotech sequencing service (Germany). The BCRP gene from
the pENTR221-hBCRP vector was further transferred to a modified Bac-to-bac
vector using the Gateway cloning system (Invitrogen, USA).
4.2.3 PRODUCTION OF MEMBRANE VESICLES
Sf9-BCRP  and  Sf9-MRP2  vesicles  (I,  II,  and  IV)  were  produced  using  a
modification  of  the  method  presented  by  Chu  et  al.  (2004).  All  steps  were
performed at 4°C. First, cells were washed twice with buffer containing 50 mM
Tris and 300 mM mannitol (pH 7.0) and centrifuged at 800 g for 5 min. Cells
were then resuspended in membrane buffer (50 mM Tris, 50 mM mannitol, 2
mM EGTA, pH 7.0) and homogenized by making 40 strokes with a tight fitting
Dounce homogenizer. Lysates were incubated on ice for 1 h. Cell debris was
removed  by  centrifugation  at  800  g,  10  min,  4°C  and  the  supernatant  was
subsequently  centrifuged  at  100  000 g  for  1  h  15  min.  Finally,  the  resulting
pellet  was resuspended in membrane buffer and passed 20 times through a
27G needle.
The  Sf9-BCRP  vesicles  were  loaded  with  cholesterol  to  improve  the
dynamic range of the assay (Telbisz et al., 2007)(I, II, IV). Membranes were
incubated  for  20  min  on  ice  in  membrane  buffer  with  a  water-soluble
randomly methylated β-cyclodextrin cholesterol complex at a final cholesterol
concentration of 2.5 mM. Excess cholesterol/cholesterol complex was
removed by repeating centrifugation at 100 000 g, after which the pellet was
resuspened in membrane buffer and homogenized with a needle. The final
concentration of cholesterol in the membrane vesicles was approximately 100
μg cholesterol/mg total protein according to the Amplex Red assay kit.
The  HEK293-BCRP  vesicles  used  in  publication  III  were  prepared  as
follows. Cells were resuspended in Tris-sucrose (TS) buffer (10 mM Tris, 250
mM sucrose, pH 7.4) and homogenized with the Dounce homogenizer as were
the  Sf9  cells.  The  lysate  was  centrifuged  for  20  min  at  4  000  g,  4°C.  The
resulting supernatant was subjected to further centrifugation for 1 h 30 min,
21 000 g at 4°C. The supernatant was discarded and the remaining pellet was
resuspended  in  TS  buffer  and  passed  20  times  through  a  27G  needle  to
homogenize the suspension and form vesicles.
The protein concentration of all vesicle preparations was assayed using the
Bio-Rad protein assay which is based on the Bradford method (Bradford,
1976). Vesicles were diluted to a stock concentration of 5 mg/ml (Sf9 vesicles,
I-IV) and 1.5 mg/ml (HEK293 vesicles, III).
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4.2.4 VESICULAR TRANSPORT ASSAY
The  activity  of  BCRP  and  MRP2  was  studied  in  all  publications  using  the
vesicular transport assay. The probe substrates used in this study were 5(6)-
carboxy-2’,7’-dichlorofluorescein (CDCF) and estradiol-17β-glucuronide
(E217G) for MRP2 and Lucifer  Yellow (LY) and estrone-3-sulphate (E1S) for
BCRP (Figure 5).
Figure 5 Molecular structures of the compounds used as BCRP and MRP2 substrates in the
vesicular transport assay.
The Sf9 transport assays were performed as a modification of the PREDIVEZ
Vesicular Transport Assay kit protocol (Solvo, Hungary). In the assay, vesicles
are diluted in buffer  containing 40mM MOPS-Tris  (pH 7.0),  60 mM KCl,  6
mM MgCl2 and  transporter  substrate.  In  MRP2 assays,  1.9  mM glutathione
was included in reactions. In inhibition assays, probe substrates LY (50 μM)
and CDCF (5 μM) were used and test compounds (dissolved in DMSO) were
included  in  the  mixture  at  50  μM  in  the  initial  screening  (II,  IV).  The
aggregation of selected test compounds in assay conditions was studied with
nephelometry (Nepheloscan Ascent, Thermo Fisher Scientific, USA)(II, IV).
The DMSO concentration in the assays did not exceed 2%. In publication I,
0.1% or 1%   essentially fatty acid free bovine serum albumin was included in
assays and the kinetics of BCRP-mediated LY transport as well as the MRP2-
mediated transport of CDCF and E217G was studied.
In  the  assays,  vesicles  were  first  preincubated  at  the  appropriate
temperature, then Mg-ATP (4 mM final concentration of ATP) was added to
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start the reaction. Reactions were stopped with cold washing buffer (40 mM
MOPS-TRIS (pH 7.0) and 70 mM KCl), filtered on MultiscreenHTS glass fiber
filter plates (Millipore, USA) and washed five times with the buffer. The key
assay  parameters  for  each  of  the  substrates  are  indicated  in  Table  4.  The
protocol was slightly modified for the studies performed with HEK293-BCRP
vesicles (III). Vesicles (15 μg) were incubated in TS buffer with substrate, 10
mM MgCl2 and 4 mM ATP or AMP (background control).  A mixture of 3H-
labelled and unlabelled E1S was used in E1S assays with a final concentration
of  1  μM.  Reactions  were  terminated  at  appropriate  times  with  ice-cold  TS
buffer, filtered and washed twice.
Table 4 Assay parameters of the substrates used in the VT assay
BCRP substrates MRP2 substrates
LY E1S CDCF E217G
Concentration in
inhibition assays
50 μM N.A. 5 μM N.A.
Preincubation time * 5 min 5 min 10 min 15 min
Incubation time with ATP 10 min 2 min 30 min 8 min
Assay temperature 37°C 32°C 37°C 37°C
Analysis Fluorescence Scintillation
counting
Fluorescence LC-MS/MS
* Preincubation not used in HEK293 vesicle assays. N.A. = not applicable
After  drying,  the  LY  and  CDCF samples  were  eluted  with  0.1  M NaOH and
collected on a 96-well plate. Before fluorescence detection, LY samples were
treated with an equal volume of 0.1 M HCl. Fluorescence was measured with
Varioskan Flash (ThermoFisher Scientific, Finland). Excitation and emission
wavelengths  were  510  and  535  nm  for  CDCF  and  430  and  538  nm  for  LY,
respectively. E217G samples were eluted with 0.1 M ammonium hydroxide and
subjected to mass spectrometric analysis with ultra-performance liquid
chromatography-tandem mass spectrometry (UPLC-MS/MS) (for details, see
publication  I).  E1S  samples  were  measured  with  a  Wallac  1450  Microbeta
Trilux  scintillation  counter  (Perkin  Elmer,  USA)  after  addition  of  50  μl  of
OptiPhase HiSafe 2 scintillation cocktail to each well (III).
4.2.5 INTERFERENCE ASSAYS
There is a possible caveat in using fluorescence based assays, especially when
working with coloured test compounds. Many compounds possess the ability
to either quench (i.e. extinguish) probe fluorescence or produce their own
fluorescence which may disturb the probe signal. This can result in the false
interpretation of the data. For example, a highly quenching test compound
may appear to decrease uptake since the fluorescence signal is decreased, but
may in reality have little effect on transport.
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The natural compound library used in Publication II, and the food additives
studied  in  Publication  IV,  contained  several  coloured  and  potentially
interfering compounds. To rule out any interference, the effect of the test
compounds  on  the  fluorescence  of  the  assay  probes  (CDCF  and  LY)  was
studied as detailed below. Test compounds were diluted in the solvent used in
the measurement step of the transport assay, i.e. 0.1 M NaOH (CDCF samples)
or 1:1 0.1 M NaOH/0.1 M HCl (LY samples). Due to the nature of the assay, the
concentration of the test compound in the final measurement step is unknown.
Therefore the testing was performed at the highest possible concentration,
assuming that all of the test compound was retained in the final elute. Wells
were  spiked  with  an  appropriate  amount  of  LY  or  CDCF  that  resulted  in  a
control signal corresponding to the fluorescence signals seen in the control
wells  in  the  vesicle  assays.  Fluorescence  was  measured  as  in  the  vesicular
transport assay. The obtained fluorescence values in the presence of the test
compounds were compared to values in the control  wells  (DMSO instead of
test compound). Further testing at lower test compound concentrations was
performed for selected compounds in publication IV.
4.2.6 IMMUNOBLOTTING
The relative expression level of BCRP in the vesicle preparations was studied
with  immunoblotting  to  see  whether  altered  expression  could  explain  the
observed  differences  in  activity  (III).  Samples  for  western  blotting  were
prepared by mixing vesicles with 2 x Laemmli sample buffer and separating
them on a commercial 10 % SDS-Page gel (Mini-PROTEAN TGX Stain-Free
gel).  Samples  were  blotted  to  a  0.45  μm nitrocellulose  membrane  and  then
blocked with 5% (w/v) skimmed milk solution. Membranes were probed for 1
h with the anti-human BCRP mouse monoclonal antibody BXP-21 (1:5000 in
5%  w/v  skimmed  milk  in  TBS-0.1%  Tween  20)  for  BCRP  detection.  After
washing  with  TBS-Tween,  the  secondary  antibody,  goat  Anti-Mouse  IgG
antibody (H+L) HRP conjugate (1:10 000) was applied in 2.5% (w/v) skimmed
milk in TBS-Tween for 1 h. The membrane was finally washed with TBS-Tween
and the Amersham ECL Prime Western blotting detection reagent was used to
visualize  the  bands.  The  membrane  was  imaged  using  the  ChemiDoc  XRS+
imager  from Bio-Rad.  The  total  protein  content  in  each  lane  was  visualized
using the Stain-free technology from Bio-Rad. This data was used to normalise
the band intensity of the BCRP specific signal according to the Stain-free
workflow (Bio-Rad)  using  the  Image  Lab  software  v.  5  (Bio-Rad).  The  final
data was presented as a relative band intensity (%) compared to the WT BCRP.
4.2.7 IMMUNOFLUORESCENCE MICROSCOPY
In publication III, the localization of transduced BCRP in HEK293 cells was
studied using immunofluorescence microscopy. LabTek 8-well chamber slides
(Nunc,  Denmark)  were  coated  with  0.1  mg/ml  poly-D-lysine  solution  to
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improve  the  adhesion  of  HEK293  cells,  which  were  seeded  at  0.2  x  105
cells/chamber and allowed to attach for 24 h. Cells were then transduced using
BCRP variant baculovirus. Transduction efficiency was improved by adding 5
mM  sodium  butyrate  to  the  medium.  Cells  were  fixed  with  4%
paraformaldehyde solution 24 h after transduction. Cells were permeabilised
with  0.5% saponin  in  PBS before  labelling  BCRP with  the  BXP-21  antibody
(1:2000). Goat anti-mouse IgG (H+L)-Alexa Fluor 488 secondary antibody
(1:200) was used as the secondary antibody. 25 μg/ml DAPI was used to stain
the nuclei of the cells. Normal mouse IgG (1:400) was applied as a control in
one well. A Leica DM6000B wide-field microscope (Leica Microsystems,
Germany) was used for imaging with 40x magnification. The experiments
were performed on two separate batches of transduced HEK293 cells.
4.2.8 DATA ANALYSIS
In all vesicle assays, reactions were performed in triplicate in the presence and
the  absence  of  ATP  (I-IV).  ATP-dependent  transport  was  calculated  as  the
difference between these two values. The dynamic range of the assay was
evaluated  based  on  the  ratio  of  observed  transport  in  the  presence  and  the
absence of ATP. In inhibition experiments, data was normalised to the ATP-
dependent uptake in the vehicle control. Compounds that decreased transport
to ≤ 50% at 50 μM were regarded as potential inhibitors (II, IV).
Curve  fitting  was  performed  using  GraphPad  Prism  version  6.05
(GraphPad Software Inc., USA). The kinetic parameters of transport for CDCF
and LY were calculated by fitting the Michaelis-Menten equation (I, III):
(2) 𝑣 = ௏೘ೌೣ×஼௄೘ା஼
where v is the measured ATP-dependent transport, C is the concentration of
the substrate, Vmax is  the  maximal  transport  and  Km is the substrate
concentration at which the transport is 50% of Vmax. For E217G, the allosteric
sigmoidal model of kinetics was used (I):
(3) 𝑣 = ௏೘ೌೣ×஼೓௄೓ೌ೗೑೓ ା஼೓
where Khalf is the substrate concentration required for 50% Vmax, h is the Hill
slope and other parameters are the same as in the basic Michaelis-Menten
equation.
In  the  inhibition  assays  (I,  II,  IV),  the  concentration  required  for  50%
inhibition (IC50) was calculated using the four parameter logistic curve:
(4) 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 = 𝐵𝑜𝑡𝑡𝑜𝑚 +  ்௢௣ି஻௢௧௧௢௠ଵା( [಺]಺಴ఱబ)೓
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where Response is the ATP-dependent transport normalized to the control,
Bottom and Top are the plateaus of the maximal and minimal inhibition, [I] is
the inhibitor concentration and h is the Hill slope.
Molecular descriptors were calculated with PaDEL-Descriptor (Yap, 2011)
and ACD/Labs version 8.0 (Advanced Chemistry Development, Inc., Canada)
(II, IV). In Publication II, principal component analysis (PCA) for the library
compounds was performed with Simca-P version 10.5 (Umetrics, Sweden).
The consequences of  the BCRP polymorphisms were predicted using online
tools  PolyPhen2  (Adzhubei  et  al.,  2010)  and  SIFT  Human  Protein  service
(Kumar  et  al.,  2009).  The  Uniprot  entry  Q9UNQ0,  corresponding  to  WT
BCRP, was used as a template for the predictions.
4.2.9 STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism version 6.05 in all
cases. The extra-sum-of-squares F-test was used to evaluate whether there was
a  significant  difference  in  calculated  kinetic  parameters  (Km and  Vmax) in
publications  I  and  III.  The  statistical  significance  of  differences  between
transport in the presence of 0.1% and 1 % BSA was analysed using the unpaired
t-test  in  publication  I.  Finally,  in  publication  III,  one-way  ANOVA with  the
Dunnett’s post hoc test  was  applied  to  verify  the  statistical  significance  of
differences in ATP-dependent transport or BCRP expression between the
variant  and  WT  forms  of  BCRP.  In  all  cases, p values below 0.05 were
considered significant.
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5 SUMMARY OF THE MAIN RESULTS
5.1 THE EFFECT OF ALBUMIN ON MRP2 AND BCRP IN
THE VESICULAR TRANSPORT ASSAY (I)
The addition of albumin is known to affect the kinetic parameters of metabolic
enzymes (UGTs and CYP450s) measured in vitro in human liver microsomes
or membrane preparations of recombinant enzymes. The mechanism behind
the ‘albumin effect’ has been proposed to be inhibition of UGTs and CYPs by
fatty acids released from the membrane preparations. Metabolic enzymes and
transporters have an overlap in substrate and inhibitor specificity and similar
membrane preparations are used to study transport by BCRP and MRP2 using
the vesicular transport (VT) assay. Therefore, it was investigated whether
albumin  could  affect  the  kinetic  parameters  of  transport  in  this  assay.  The
inclusion of 0.1% bovine serum albumin in the VT assay increased the maximal
transport activity of CDCF and E217G by MRP2 by 110% and 55%, respectively
(Figure 6A). Only a 28% increase of LY transport was seen in BCRP vesicles
(Figure  6B).  The  Km of  transport  was  not  significantly  altered  in  any  of  the
cases.  The  albumin  effect  was  sensitive  to  protein  amount,  but  not  to  the
cholesterol  loading of  the BCRP vesicles.  Using 1% BSA resulted in a larger
albumin effect than 0.1% BSA in one case only. Finally, whether fatty acids also
inhibit  MRP2 or BCRP transport  was investigated.  The results  indicate that
BCRP can be inhibited by oleic acid, the most abundant fatty acid in Sf9 cells,
and the apparent calculated IC50 was 28 μM. Results for MRP2, however, were
inconclusive, because oleic acid severely compromised the integrity of the
vesicles.
Figure 6 The albumin effect on the transport activity of MRP2 and BCRP. The ATP-
dependent transport of 5(6)-carboxy-2’,7’-dichlorofluorescein (CDCF) in MRP2 vesicles (A) and
Lucifer yellow (LY) in BCRP vesicles (B) was studied in the prescence and absence (control) of
0.1% BSA. Data points are normalized to the calculated Vmax of the control and represented as
mean ± SD (n=3-4). Curves represent fitting to the Michaelis-Menten equation. Modified from Deng
et al. 2016.
Summary of the main results
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5.2 INHIBITION OF BCRP AND MRP2 BY NATURAL
COMPOUNDS AND THEIR DERIVATIVES (II)
The interaction of 124 natural compounds and natural compound derivatives
with BCRP and MRP2 was studied using the VT assay. In the initial screening
at  50  μM,  45  inhibitors  of  BCRP  were  identified  (36%  of  all  library
compounds),  whereas  only  four  MRP2 inhibitors  were  found (Figure  7).  By
broadening the criteria, altogether six potential dual inhibitors of BCRP and
MRP (gossypin, myricetin, morin, nordihydroguaiaretic acid, octyl gallate, and
silybin) were selected for IC50 studies. The range of determined IC50 values was
0.642 – 13.1 μM for BCRP and 19.2 – 49.8 μM for MRP2 (Table 5). Flavonoids
were the most important compound group for BCRP inhibition:   86% of  all
flavonoids inhibited BCRP. The C-ring 2,3 double bond and C4-ketone seemed
to be beneficial  for  inhibition since many flavones and flavonols,  flavonoids
with these elements, were among the most potent inhibitors. Molecular
weight, LogD7.4, the number of aromatic atoms, and the number of rings were
identified as descriptors that distinguish BCRP inhibitors from non-inhibitors.
Analysis  of  MRP2  inhibitor  properties  was  not  possible  due  to  the  small
number of identified inhibitors.
Figure 7 Results of the natural compound library screening. Bars represent the relative
transport activity in the presence of the test compounds normalised to the control (vehicle only).
Compounds are sorted according to their activity to illustrate the number of hits (relative transport
activity < 50%) identified in the screens for each transporter and are not in comparable order
between graphs. Error bars are omitted for clarity.
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Table 5 Dual inhibitors of BCRP and MRP2 identified in the natural compound library. The
IC50 values were calculated from dose-response curves using GraphPad Prism v.6.05 and are
presented with the 95% confidence interval (95% CI).
Inhibitor Structure
IC50 (μM) (95% CI)
BCRP MRP2
Gossypin 9.66(6.50 - 14.4)
30.3
(21.9 í 41.9)
Morin 0.642(0.533 - 0.773)
25.1
(19.6 í 32.6)
Myricetin 0.835(0.739 - 0.946)
47.5
(37.5 í 60.2)
Nordihydro-
guaiaretic acid
13.1
(10.0 - 17.0)
39.9
(34.6 í 46.0)
Octyl gallate 10(6.38 - 15.7)
19.2
(14.8 í 24.9)
Silybin 1.45(1.08 - 1.99)
49.8
(42.4 í 58.5)
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5.3 EFFECTS OF TRANSMEMBRANE DOMAIN
VARIANTS ON BCRP EXPRESSION AND ACTIVITY
(III)
The effects of nine naturally occurring, non-synonymous transmembrane
polymorphisms (G406R, F431L, S441N, P480L, F489L, M515R, L525R,
A528T,  and  T542A)  on  BCRP  activity  and  expression  were  studied.  BCRP
variants were produced using site-directed mutagenesis and then expressed in
insect-derived Sf9 and human-derived HEK293 cells using the baculovirus
expression system. The transport activity of the variants was studied using the
VT assay with probe substrates LY and E1S. Reduced transport compared to
the WT was seen for all variants. For eight out of nine variants, LY transport
was less than 25% of WT in both Sf9 and HEK293 vesicles, whereas the A528T
variant decreased transport by approximately 50% in both systems (Figure 8).
Similar results were obtained with the physiological BCRP substrate E1S.
Figure 8 Relative ATP-dependent transport of Lucifer yellow (LY) in BCRP variant vesicles.
The transport of 50 μM LY by the BCRP variants was studied using Sf9 (solid bars) or HEK293
(open bars) veicles. The data is normalised to the transport activity of wild type (WT) BCRP and
presented as the mean with standard deviation from two separate experiments performed in
triplicates. According to one-way ANOVA with the Dunnett’s post hoc test, the transport activity in
all preparations was significantly different from WT BCRP (p < 0.0001).
BCRP was detected in Western blots of all BCRP vesicle preparations, but the
variant’s  expression  levels  tended  to  be  lower  than  WT  (Table  6).  Relative
expression levels were lower in HEK293 than Sf9 vesicles. Only negligible
amounts of G406R, S441N, and M515R could be detected in HEK293 vesicles.
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Immunofluorescence studies showed that some of the observed results in
function  and  expression  could  be  explained  by  improper  localization  of  the
variants inside the cell (Table 6).
Table 6 Effects of studied transmembrane region polymorphisms on BCRP expression
Nucleotide
change
Amino acid change Relative expression (± SD) Localization
Sf9 HEK293
1216G>A G406R   42 (± 3.2)        1.1 (± 0.57) Intracellular
1291T>C F431L 110 (± 9.6) 54 (± 14) Cell surface
1322G>A S441N  49 (± 17)      1.9 (± 2.4) Intracellular
1439C>T P480L   81 (± 8.4) 19 (± 7.2) Cell surface
1465T>C F489L  84 (± 15)      18 (± 11) Cell surface
1544T>G M515R  45 (± 13)     1 (± 0.82) Intracellular
1574T>G L525R  78 (± 20)      25 (±24) Intracellular
1582G>A A528T   110 (± 35)      49 (± 11) Cell surface
1624A>G T542A 120 (± 22) 28 (± 9.8) Cell surface
5.4 INHIBITION OF BCRP AND MRP2 BY FOOD
ADDITIVES (IV)
The  interaction  of  food  additives  with  ABC  transporters  remains  an
overlooked area of possible food-drug interactions. In this study, 25 food
additives, including preservatives, colourants, and sweeteners were tested for
BCRP  and  MRP2  inhibition  using  the  VT  assay.  None  of  the  preservatives
inhibited either transporter, but several colourants inhibited both BCRP and
MRP2 (Figure 9). All azo dyes inhibited one or both of the transporters. Allura
red AC, brilliant black BN and carmoisine inhibited BCRP and MRP2, sunset
yellow FCF and tartrazine inhibited BCRP. Additionally, brilliant blue FCF, a
triarylmethane  dye,  inhibited  MRP2  transport  and  natural-based  dyes
chlorophyllin  sodium  copper  complex  and  curcumin  inhibited  both
transporters. The only sweetener with inhibitory activity was neohesperidin
dihydrochalcone, which was identified as the most potent BCRP inhibitor in
dose-response studies (IC50 =  0.86  μM).  Brilliant  blue  was  the  most  potent
MRP2 inhibitor with an IC50 of 3.22 μM.
Summary of the main results
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Figure 9 Relative transport activity of BCRP and MRP2 in the presence of food additives.
Twenty five food additives were tested at 50 μM for their potential to inhibit BCRP (black bars) and
MRP2 (grey bars) in the vesicular transport assay. The probe substrates used were 50 μM Lucifer
yellow and 5 μM CDCF for BCRP and MRP2, respectively. Bars show the mean ± SD of ATP-
dependent transport normalised to the transport in the presence of vehicle (DMSO) only (n=3).
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6 DISCUSSION AND FUTURE PROSPECTS
In  this  thesis,  different  compounds’  manner  of  interaction  with  BCRP  and
MRP2 was studied by using the VT assay. The method was successfully applied
to  screen  for  inhibitors  of  BCRP  and  MRP2  and  to  evaluate  the  effects  of
transmembrane  helix  variants  on  BCRP  transport  activity.  The  effect  of
albumin on the kinetic parameters derived using the assay was also studied.
The results of the thesis publications and the future prospects of transporter
studies are discussed below.
6.1.1 ’ALBUMIN’ EFFECT AND IVIVE
In publication I, the effect of bovine serum albumin (BSA) in the VT assay was
assessed to determine whether it would affect the observed transport and
possibly influence IVIVE. A moderate, but significant increase was observed
in Vmax values,  but this  was partly  counteracted by the slight increase in Km
values leading to minor changes in calculated clearance values. Unfortunately,
unlike  the  metabolic  studies,  it  was  impossible  to  compare  the  kinetic
parameters to in vivo data, since this was unavailable for the probe substrates
used in the studies. In vivo validation data for transporter kinetics is generally
scarce due to the interplay between transporters and their presence at several
distinct barrier sites, simultaneously effecting many stages of disposition. This
is in contrast to metabolic enzymes that are mainly restricted to either the liver
or intestine or both  (Zhang & Huang, 2013). In view of improvements in the
validation of methods, studies showing extrapolation even between two
different in vitro systems (Kunze et al., 2014; Vildhede et al., 2016) are likely
to be of benefit.
The data suggests that albumin could affect the in  vitro  –  in  vivo
extrapolation, but the effect on the transporters and substrates studied here
seems to be small. A similar level of variability may also arise from inter-batch
variation in vesicles or inter-, even intra-laboratory practices. Indeed, the
loading  of  Sf9-BCRP  vesicles  with  cholesterol  has  a  greater  effect  on  Vmax
values, although it did not influence the BSA effect in this study. For BCRP,
the  observations  from  this  study,  as  well  as  from  others  (Pal  et  al.,  2007;
Telbisz et al., 2007), suggest that for the kinetic IVIVE of BCRP substrates, a
mammalian  system  where  BCRP  is  in  its  native  environment  should  be
favoured.  Regarding  the  ‘albumin  effect’,  it  should  be  noted  that  we  only
studied two transporters and three substrates altogether. It is known from
studies with UGTs that the albumin effect is substrate and enzyme-dependent
(Manevski et al., 2013). Taken together, it cannot be concluded whether or not
the addition of BSA would improve IVIVE for other drugs, but rather that the
possibility of BSA influence should be considered if BSA is included in assays.
Discussion and future prospects
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6.1.2 INHIBITION OF BCRP AND MRP2
In publication II and IV, the inhibition of BCRP and MRP2 was investigated.
There are several reasons why it is of interest to study the inhibitors of ABC
transporters. Initially, after the identification of transporters in multidrug
resistant cell lines, the main focus was on finding potent, non-toxic inhibitors
that could be used in vivo to  overcome multidrug  resistance.  Despite  many
efforts, this strategy has so far yielded disappointing results and finding ABC
transporter inhibitors that are suitable for clinical use has been difficult (Chen
et  al.,  2016).  Moreover,  the  strategy  can  be  criticized  on  the  basis  that
alongside increased permeation into tumours, the systemic administration of
inhibitors may cause adverse effects by increasing exposure in other tissues as
well. Due to these limitations, a timelier, challenging question is the quest for
specific inhibitors that could aid in elucidating the roles of specific
transporters  when  several  proteins  are  involved  in  drug  PK.  In  addition  to
identifying useful inhibitors, inhibition studies can reveal information about
the molecular properties that are needed for interaction with transporters. It
should be kept in mind, however, that inhibitors may bind to transmembrane
regions distinct from the transport binding site or even interact with the NBDs.
Therefore, the properties of inhibitors may differ from those of substrates.
Lastly, the inhibition of transporters might be studied to answer the question
of whether there is a possibility for transporter-mediated DDIs or food-drug
interactions. In publication II, a library of natural compounds and their
derivatives was screened to answer these last two questions, i.e. identify the
properties  of  inhibitors  and  discuss  interaction  potential  with  BCRP  and
MRP2.  Similarly,  in  publication  IV,  it  was  hypothesised  that  food  additives
could inhibit these intestinal transporters and the VT assay was used to study
this interaction.
In the natural compound library, a major compound group that contained
29% of compounds, was flavonoids. Flavonoids are abundant in our everyday
diet and they are responsible for much of the taste and the colour of fruits and
vegetables  (Ross  &  Kasum,  2002).  Although  the  interaction  of  BCRP  with
flavonoids has been studied previously (Cooray et al., 2004; Imai et al., 2004;
Zhang  et  al.,  2004;  Ahmed-Belkacem  et  al.,  2005;  Zhang  et  al.,  2005a;
Katayama et al., 2007; Pick et al., 2011; Juvale et al., 2013), it was interesting
to find that almost all of the studied flavonoids were able to inhibit BCRP. On
the contrary, the amount of hits for MRP2 (3%)  was much lower than expected
based on previous screenings, where approximately 20% of tested compounds
were identified as inhibitors (Pedersen et al., 2008; Wissel et al., 2015). The
low  number  of  hits  could  be  due  to  the  composition  of  the  library,  which
consisted of distinct compound groups, including flavonoids, which are known
to have low interaction with MRP2 (van Zanden et  al.,  2005).  Interestingly,
BCRP and MRP2 showed clear overlap of inhibition in the food additive study,
whereas preliminary data on P-glycoprotein inhibition by the same compound
set indicated inhibition by only one compound (data not shown).
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Although it was not pursued in depth in this study, the data suggests that
there is a potential for the analysis of the structure-activity relationships (SAR)
of the flavonoids, since there were some trends noted even in the preliminary
screening. From this data, we were able to identify some important structural
features  such  as  the  C-ring  ketone  and  2-3  double  bond.  Further  dose-
response analysis and IC50 determination may reveal even greater differences
between structural features, because several flavonoids were able to almost
abolish transport at the 50 μM concentration used in the studies. The SARs of
flavonoids have indeed been investigated by other groups in the search for
potent BCRP inhibitors (Ahmed-Belkacem et al., 2005; Zhang et al.,  2005a;
Katayama et al., 2007; Pick et al., 2011).
To further understand flavonoid interactions, it would be extremely
interesting to perform molecular modelling and docking studies to see which
parts of the protein the flavonoids interact with. It has been proposed that
certain flavonoids might interact with the NBDs of ABC transporters (Matsson
et al., 2009), but this finding is not supported as a general mechanism by the
results presented here due to the observed differences in BCRP and MRP2
inhibition patterns. The NBD interaction proposed by Matsson et al. (2009)
was based on docking to a structure based on the NBD of MRP1, but docking
studies in general have been limited by the lack of structural information on
full proteins. Obtaining the high-resolution crystal structures of mammalian
ABC  transporters  has  been  challenging,  and  until  recently  the  structure  of
mouse P-glycoprotein, published by Aller et al. (2009), was the most relevant
available  structure  for  human  ABC  drug  transporters.  Since  P-glycoprotein
represents the typical ABC organization with two TMDs and two NBDs, this
crystal  structure  has  had  limited  use  for  the  modelling  of  BCRP and  MRP2
which deviate from the basic structure. The recently published structures of
bovine ABCC1/MRP1 (Johnson & Chen, 2017) and human heterodimer
transporter ABCG5/ABCG8 (Lee et al., 2016), however, are likely to greatly
improve the quality of homology models for MRP2 and BCRP, respectively. In
fact, a homology model of BCRP that is based on the ABCG5/ABCG8 structure
has been published recently (Laszlo et al.,  2016). Docking studies using this
model support the conception that BCRP has several binding sites.
The existence of multiple binding sites is a challenge for SAR analyses of
BCRP  and  MRP2,  because  it  may  result  in  probe-dependent  effects  of
modulators. In this regard, docking analysis could aid in the interpretation of
in vitro interaction data. Additional information about binding sites can also
be gained from protein structures captured in the ligand-bound state, as has
been  done  with  the  crystal  structure  of  mouse  P-glycoprotein  (Aller  et  al.,
2009). Based on structural data, it has recently been suggested that unlike P-
glycoprotein and BCRP, MRP1 recognizes its substrates from the cytoplasm
and not the lipid bilayer (Johnson & Chen, 2017). This may explain some of
the differences observed between the interactions of compounds with BCRP
and MRP2, if we consider MRP2 to resemble MRP1 in this respect. This is an
example of how the increase in structural information can quickly provide a
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better understanding of drug binding and transport. This knowledge could be
further  used  in  modifying  and  prioritising  lead  compounds  in  drug
development. With BCRP though, it remains to be seen whether future protein
crystallisation  studies  will  shed  light  on  the  higher  order  oligomeric  states
proposed by other methods (Xu et al., 2004; Wong et al., 2016).
The  fact  that  this  and  previous  studies  (Cooray  et  al.,  2004;  Imai  et  al.,
2004; Zhang et al., 2004; Tan et al., 2013) suggest that many flavonoids can
inhibit  BCRP may  be  of  importance,  because  they  are  abundant  in  our  diet
(Ross & Kasum, 2002; Manach et al., 2004). Based on in vitro data, it has been
proposed,  for  example,  that  flavonoids  in  orange  and  grapefruit  juice  could
alter  dasatinib  PK  through  the  inhibition  of  BCRP  (Fleisher  et  al.,  2015).
However, the challenge of extrapolating the in vitro findings from the vesicle
studies  to  a  clinical  setting,  is  that  some  of  the  studied  compounds  are
hydrophilic  and  may  have  limited  access  to  the  inside  of  the  cell  and  the
intracellular domains of the transporters in vivo. In this respect, the VT assay
may overestimate the potency of the compounds, because the measured IC50
values  are  related  to  the  intracellular  concentrations.  Indeed,  for  low
permeability compounds, a shift is sometimes observed between IC50 values
from vesicle- and cell-based assays (Szeremy et al., 2011; Poirier et al., 2014).
Although the expected intestinal in vivo concentrations could easily exceed the
determined IC50 values for the studied  dyes and the natural compounds taken,
for example, as herbal supplements, the intracellular levels may remain low
enough not to result in significant inhibition. Therefore, the results should be
verified in cell-based assays, before further conclusions on the possible in vivo
significance can be made. On the other hand, our studies did not consider the
interactions of metabolites that might be formed from the studied compounds
in vivo. Flavonoids, for example, are good substrates of UGTs, because they
typically  contain  several  phenolic  groups  (Chen  et  al.,  2014).  Due  to  the
increased hydrophilicity of metabolic conjugates, they often require active
transport to escape cells, meaning that there is the potential for interaction
with efflux transporters. MRP2, in particular, may be prone to interaction with
these metabolites since it is known to favour glucuronide conjugates (Morris
&  Zhang,  2006;  Nies  &  Keppler,  2007;  Alvarez  et  al.,  2010).  In  fact,  the
interaction of drug metabolites with transporters and their role in drug-drug
interactions has been brought to attention by Zamek-Gliszczynski et al. (2014)
as factor or drug efficacy and safety to be considered during drug development.
Based on the inhibition data from the natural compound library screening,
we found that molecular weight, LogD7.4, the number of aromatic atoms, and
the number of rings were important features separating for BCRP inhibitors
and non-inhibitors. These descriptors were not, however, enough to construct
a  successful  classification  model  of  this  data  using  partial  least  squares
regression (data not shown). On the other hand, the identified descriptors are
in line with those reported by others (Zhang et al., 2005a; Matsson et al., 2007;
Matsson et al., 2009). As expected based on these findings, the low molecular
weight preservatives and the sweeteners that did not contain many (aromatic)
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rings were not identified as BCRP inhibitors in the food additive studies. On
the  contrary,  the  colourants  that  were  found  to  inhibit  BCRP  are  higher  in
molecular  weight  (>350  g/mol)  and  contain  two  or  more  ring  structures.
However, the calculated LogD7.4 values  of  the  colourants  were  lower  than
expected for BCRP inhibitors, with the average and median LogD7.4 being -2.2
and -2.6. In the natural compound screening, the LogD7.4 of BCRP inhibitors
was generally > 0. The reason for this discrepancy is not known.
6.1.3 PHARMACOGENETICS
In  addition  to  studying  inhibition,  the  VT  assay  was  used  in  this  thesis  to
evaluate changes in the transport activity of naturally occurring genetic
variants of BCRP. In publication III, nine naturally occurring genetic variants
of BCRP were expressed in both Sf9 insect cells and human-derived HEK293
cells.  A  significant  decrease  in  transport  activity  was  observed  for  the  two
tested substrates, LY and E1S,  for  all  variants.  The  results  were  the  same
irrespective of the expression system. There was, however, a clear difference
between the relative expression levels of the BCRP variants between the
vesicles  from  Sf9  and  HEK293  according  to  western  blot  results.  Relative
expression levels in Sf9 cells were higher than in HEK293, implying that the
amino  acid  changes  led  to  both  altered  expression  and  function.  The  low
expression,  especially  at  the  cell  membrane,  was  verified  with
immunofluorescence  microscopy  in  the  transduced  HEK293  cells.  Why  the
studied  SVPs  lead  to  this  impaired  expression  on  the  cell  membrane  is
unknown, but it has been previously reported that the p.Q141K, p.F208S, and
p.S441N variants suffer from ubiquitin-mediated proteasomal degradation
(Nakagawa et al., 2008; Furukawa et al., 2009). Ubiquitination is a regulatory
process in the cell, which targets damaged or misfolded proteins and signals
them to be degraded. Incorrect folding and subsequent ubiquitination could
explain the low expression of p.G406R, p.M515R, and p.L525R, as observed
previously  for  p.S441N  (Nakagawa  et  al.,  2008).  This  may  also  explain  the
higher relative expression in Sf9 cells, which are grown at 27°C. It has been
shown that lower temperature can enhance the cell surface expression of the
CFTR (ABCC7) variant p.ΔF508 that suffers from misfolding (Denning et al.,
1992; Heda & Marino, 2000). However, the expression of p.Q141K, which is
located next to the amino acid corresponding to the amino acid 508 in CFTR,
was not significantly improved in HEK293 cells grown at 28°C whereas in Sf9
cells the expression was similar to WT BCRP (Saranko et al., 2013).
Although the studied variants are rare, the results indicate that patients
carrying these forms, could be at risk for aberrant effects of BCRP substrate
drugs. The p.A528T variant had approximately 50% reduced transport
activity, which is similar to the reported effects of the fairly common p.Q141K
variant  (Kondo  et  al.,  2004;  Tamura  et  al.,  2006;  Matsuo  et  al.,  2009).
Therefore, it would be expected that subjects with this SNP would be at risk
for increased exposure to, for example, rosuvastatin and sulphasalazine as the
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p.Q141K subjects (Urquhart et al.,  2008; Yamasaki et al.,  2008; Keskitalo et
al., 2009). Furthermore, the eight other variants showed even higher
impairment of activity, suggesting that their effects in vivo could  be  more
drastic. However, it is not known whether the decrease in activity would be as
significant  for  the  heterozygous  carriers  of  the  SNVs  or  what  kind  of
consequences the heterozygous combinations of the SNVs would have. For the
p.Q141K variant, for example, significant changes in atorvastatin exposure
compared  to  WT  were  seen  only  for  the  subjects  homozygous  for  p.Q141K
polymorphism (Keskitalo et al., 2009). Nevertheless, the heterozygous
combination of the fairly common c.421C>A variant allele with one of the more
rare variant alleles studied in this thesis could cause significant changes in
exposure. Indeed, in a case-report by Gotanda et al. (2015), the combination
of p.Q126X polymorphism with p.Q141K led to a more pronounced change in
sulphasalazine kinetics than heterozygous p.Q141K alone.
This  type  of  data  can  help  to  explain  interindividual  variability  in  drug
exposure  or  response,  and  the  genetic  information  could  be  utilized  for
personalized drug dosing to decrease adverse effects as has been proposed for
rosuvastatin (DeGorter et al., 2013). Vast developments in genome sequencing
techniques  over  the  last  20  years  have  reduced  the  time  and  the  cost  of
sequencing, meaning that the availability of genetic data has increased
immensely. The techniques have become so mundane, that genome
sequencing  is  even  marketed  directly  to  consumers  who  are  curious  about
their ancestry and health-related risks (Zettler et al., 2014). Despite these
advances, the implementation of pharmacogenetic testing in the clinic is not
widespread  (Dias  et  al.,  2017).  This  is  explained  by  the  gaps  in  knowledge
regarding the clinical validity and utility of testing, i.e. the difficulty of linking
specific genetic changes to outcomes as well as demonstrating the benefit of
using this genetic data, for example, for dose adjustments. Once the validity of
testing is proved, further data is needed to indicate the cost-effectiveness of
the testing. In spite of these hurdles and the need for further research, genetic
testing and personalized medicine hold promise in providing each patient with
the right drug at the right dose for the optimal therapeutic effect and decreased
adverse events.
In considering the potential consequences of altered transporter function,
it is imperative to keep in mind that the observed changes are always related
to the importance of that particular transporter in relation to other excretion
pathways.  The  theoretical  maximal  fold  increase  in  drug  exposure  if,  for
example BCRP, is completely inhibited, can be calculated as 1/(1-fe), where fe
is the fraction of the drug excreted via BCRP (Zamek-Gliszczynski et al., 2009).
The examination of this relationship shows that only when a single transporter
accounts for more than 50% of total excretion, can a more than 2-fold increase
in exposure be expected when it is inhibited or impaired. For well-tolerated
drugs  with  a  wide  therapeutic  window,  a  2-fold  change  is  unlikely  to  have
clinical significance. Therefore, the clinical significance of altered exposure
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should  always  be  considered  with  regard  to  the  therapeutic  window  of  the
drug.
Due to the overlap in the substrate specificity of ABC transporters and their
co-localisation  in  tissues,  the  dysfunction  of  BCRP,  for  example,  may  be
compensated for by increased efflux by MRP2 or P-glycoprotein. It should be
noted  that  although  the  inhibition/impairment  of  a  single  transporter  may
result in moderate changes in exposure, dual inhibition/impairment may have
more dramatic effects. Using a hypothetical dual substrate of P-glycoprotein
and BCRP, Kusuhara and Sugiyama (2009) demonstrated that the knockout
of a single transporter would result in a maximum 3-fold increase in the brain
exposure of the substrate, whereas the dual knockout would increase exposure
15-fold.
In addition to the apical ABC transporters, MRP3 and MRP4 are expressed
on the sinusoidal membrane of hepatocytes (Hillgren et al., 2013). There is still
a  need to characterise the role of  these basolateral  transporters in drug and
drug metabolite kinetics (Zamek-Gliszczynski et al., 2014). In some cases, they
might compensate for impaired canalicular efflux, but this will result in altered
pharmacokinetic consequences, because substrates are pumped back to the
systemic circulation and not bile. On the other hand, MRP3 is expressed in the
basolateral membranes of enterocytes in the intestine at levels comparable to
the  apical  ABC  transporters  (Groer  et  al.,  2013;  Drozdzik  et  al.,  2014;
Nakamura et al., 2016). MRP3 may thus mediate the entry of drug metabolites
into the systemic circulation via this route also.
6.1.4 UTILITY OF THE VESICULAR TRANSPORT ASSAY
The results of this thesis suggest that, despite its limitations, the vesicle-based
assay can provide interesting information about compound interactions with
BCRP and MRP2. The major benefits  over cell-based assays are throughput
and convenience, because after preparation, vesicles are preserved at -80°C
and can used instantly after thawing. Compared to Caco-2 cells, which require
at least three weeks to reach confluence (Hubatsch et al., 2007), this is a major
advantage.  The  96-well  format  allows  higher  throughput  and  requires  less
reagents than typical  cell  experiments.  Therefore,  the VT assay is  useful  for
screening  compound  libraries  when  material  is  limited.  Although  it  can  be
argued that the inside-out conformation of the vesicles makes this system
artificial  compared  to  whole  cells,  it  is  an  exceptional  method  for  studying
transporter interactions without confounding elements such as membrane
permeability. In this way, the VT assay is especially suited for generating data
for SAR studies. For MRP2, having direct access to the intracellular regions is
important, because many of its substrates are intracellularly formed,
hydrophilic  conjugates.  On  the  other  hand,  for  BCRP,  interaction  seems  to
require membrane partitioning in both the cellular and vesicle-based systems,
since we identified lipophilicity as an important descriptor in the VT assay as
was done before by Matsson et al. (2007) and Zhang et al. (2005a) in cell based
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systems. Therefore, the disconnect between vesicle-based and cell-based data
regarding the effective concentrations, as described above, may have less
impact and cause for concern for BCRP. Still,  the transcellular permeability
assay with cell monolayers may give more information about the contribution
of active transport in relation to passive permeability, but the vesicle system is
of value when wanting to study these processes separately.
The baculovirus system used in this thesis to express BCRP and MRP2 is a
reasonably fast and straightforward method that is widely used for protein
expression in insect cells. The system has also been modified to allow
expression in mammalian cell lines. Transient expression using the modified
BacMam expression system has been reported to yield P-glycoprotein and
BCRP cell  surface expression that  is  comparable to levels  in overexpression
systems (Shukla et al., 2012). The transient system is convenient for studying
variants, because there is no need for antibiotic selection and the maintenance
of cell clones carrying the plasmid. Additionally, the combination of data from
the Sf9 and HEK293 expression systems proved to be useful for explaining the
observed transport defects. Based on the Sf9 data only, the significant changes
in expression observed in the HEK293 system would not have been
identifiable.  On  the  contrary,  based  on  the  HEK293  data  solely,  too  much
emphasis may have been given to the expression levels as an explanation for
the low activity observed in the VT assay.
Like in any other assay,  appropriate controls  are extremely important to
ensure  the  high  quality  of  data.  When  assessing  the  transport  of  a  new
compound, it is necessary to perform studies in both transporter
overexpressing and mock infected vesicles to separate background
endogenous transport.  Although the endogenous transport  in Sf9 vesicles is
thought to be fairly low (Glavinas et al.,  2008), endogenous ATP-dependent
transport  of  some  compounds  is  activated  when  vesicles  are  loaded  with
cholesterol (unpublished observation). However, when a suitable probe
substrate with low background transport is fully characterized and validated,
it  can  be  used  to  screen  for  inhibitors  without  the  interference  of  other
transport (or metabolic) pathways. With fluorescent probes, additional testing
for  test  compound  interference  should  be  considered,  as  was  done  in
publications II and IV, because probe signals may suffer from quenching or
the intrinsic fluorescence of the test compounds. Another cause for false
positives in inhibition assays can be the ability of test compounds to disrupt
the vesicle integrity, as observed with oleic acid in publication I.
6.1.5 TRANSPORTER STUDIES IN DRUG DEVELOPMENT
The efficacy of a drug is partly dictated by its ability to reach its target in the
body (Morgan et al., 2012). The thorough understanding of the absorption,
distribution, metabolism, and elimination (ADME) properties of candidates is
needed for the assessment of the safety and the efficacy of new treatments, as
well as decrease the risk of failure in clinical trials. Because transporters can
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affect the ADME of drug molecules in the body and thus their exposure, the
interactions  between  transporters  and  drug  candidates  may  need  to  be
evaluated  during  drug  development.  This  view  is  supported  by  the  current
drug-drug  interaction  guidelines  of  both  the  US  Food  and  Drug
Administration (FDA) and the European Medicines Agency (EMA) (European
Medicines Agency, 2012; US Food and Drug Administration, 2012). The
increased appreciation of transporter involvement in PK is also evident in drug
labelling: Agarwal et al. (2013) reported an increase from 10% in 2003 to 71%
in 2011 of drug package insert leaflets containing transporter information.
Drug discovery and development is a process that proceeds according to a
typical pipeline, from compound screening to clinical studies, but in the assay
sense it is iterative and transporter studies can be useful for understanding PK
events in all phases of the process. The timing and complexity of transporter
studies should be decided on a project basis considering the indication of the
drug  (Taub  et  al.,  2013).  For  example,  studies  on  multidrug  resistance
transporters, such as BCRP and MRP2, might be prioritised when developing
new anti-cancer agents to avoid resistance. In other cases, in vitro studies such
as  those  recommended  by  the  EMA  and  FDA,  might  be  performed  in  the
preclinical  stage  or  during  Phase  I  clinical  studies.  As  the  understanding  of
transporter interactions and primary excretion routes increases along the
pipeline, more mechanistic in vitro and in vivo transporter  studies  can  be
designed to focus on these emerged concerns in Phases II and III. Transporter
studies  may  even  be  the  focus  of  postmarketing  evaluation  based  on
observations from clinical use (Tweedie et al., 2013). Vesicle-based assays can
be useful during all of these phases, since they can be utilised for screening as
well as more detailed interaction and kinetic studies to increase mechanistic
understanding.
The current challenges regarding transporter studies are to find the best
practices for performing assays and interpreting their results. This is especially
true for vesicle-based assays, since transcellular permeability studies in
monolayers still appear to be the gold standard. In this thesis, issues related to
the  VT  assay,  such  as  compound  interference  for  detection  and  vesicle
integrity,  the inclusion of  BSA as well  as  the aggregation of  test  compounds
were considered. It is acknowledged by the authorities, that the field of drug
transporter studies is constantly evolving and practices should not rely solely
on written authority guidances, but on current literature (European Medicines
Agency, 2012; US Food and Drug Administration, 2012; Tweedie et al., 2013).
Reliable in vitro data  can  help  to  cut  costs  and  decrease  the  need  for
unnecessary (pre)clinical studies (Zhang & Huang, 2013). Further experience
will help to refine proposed transporter decision trees and find optimal,
possibly laboratory-specific, cut-off criteria that avoid false negative results,
which might cause safety concerns, as well as false positives, which can lead to
needless in vivo studies (Tweedie et al., 2013; Zhang & Huang, 2013).
It  is  recommended that  IC50 values by themselves should not be used to
evaluate the consequence of DDIs, but only evaluate the need for in vivo
Discussion and future prospects
58
studies (Tweedie et al., 2013). However, IC50 data, such as that generated with
the VT assay, incorporated into PBPK models may provide insight into DDI
risk.  PBPK  modelling  may  also  help  to  design  better in vivo studies for
capturing DDIs, since the presence of the interaction may be dependent on the
dosing scheme applied in the study (Zhao et al.,  2011; Tweedie et al.,  2013).
Although the validation of in vitro transporter data is difficult, isolated in vitro
systems are essential to be able to solve the roles of specific transporters. The
complexity of BCRP interactions, for example, is evident by looking at the data
presented  by  Lee  et  al.  (2015),  for  compounds  that  might  be  considered  as
potential in vivo BCRP inhibitors: The involvement of other transporters or
metabolic enzymes was reported for all of the eleven compounds. By
combining data from different assays in PBPK models, the interplay and the
roles  of  the  different  ADME  processes  might  be  resolved.  Using  the  PBPK
approach, in vitro data  may  be  used  to  its  full  potential  to  help  guide  and
streamline decision making (Jamei et al., 2009).
PBPK modelling has made advances in the past decades for a multitude of
reasons  such  as  the  increased  characterisation  of in vitro systems,
improvements in scaling paradigms, the development of computing power as
well  as  the  availability  of  commercial  PBPK  software  (Jamei  et  al.,  2009;
Rowland et al., 2011). PBPK models of different complexity that incorporate
transporter data can be used in many stages of drug development and refined
during the process to provide more quantitative data (Rowland et  al.,  2011;
Zhao et al., 2011). One of the advantages of PBPK simulations is that they can
be used to study possible outcomes in specialized populations. For example,
the  data  concerning  BCRP  variants,  generated  in  publication  III,  could  be
incorporated into a PBPK model to understand in vivo consequences. PBPK
modelling could also be used to optimise dosing in these patients. Simulations
based on virtual populations can help to capture the variability in patients and
predict PK in special populations such as children and the elderly. However,
for this goal to be achieved, more information is needed on the maturation and
the  expressional  changes  of  transporters  and  metabolic  enzymes  that  occur
with  age  (Zhao  et  al.,  2011).  This  is  another  area  in  which  the  proteomic
techniques will provide further insight.
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7 CONCLUSIONS
BCRP is an ABC transporter that has the ability to interact with a wide range
of structurally different compounds. The inhibition of BCRP in vivo can lead
to increased drug exposure and adverse effects, which is why BCRP interaction
should be explored. The same principle applies for MRP2, although the clinical
significance  of  MRP2 in  drug  disposition  is  more  elusive.  Interactions  with
BCRP and MRP2 are difficult to predict based on molecular properties due to
the existence of multiple binding sites and the limited knowledge of the protein
structure. Because there is an overlap of transporter specificities and a lack of
transporter-specific inhibitors, it is important to study the transporters in
isolated systems such as the vesicle-based assay used in this thesis.
The publications have shown that although it is difficult to validate kinetic data
from  the  vesicle-based  assay,  the  assay  can  be  beneficial  for  evaluating  the
ability of compounds to inhibit efflux transporters. The inclusion of BSA in the
assay  can  increase  transport  rates,  but  the  albumin  effect  may  be  either
transporter-  or  substrate-dependent  or  both.  Based  on  the  results,  BCRP is
susceptible to inhibition by natural compounds, especially flavonoids, which
can  be  present  in  our  everyday  diet.  Although  the  interaction  of  these
compounds  with  MRP2  was  low,  certain  food  colorants  could  inhibit  both
transporters. This suggests that the consumption of certain foods could cause
inhibition of intestinal BCRP and MRP2 and result in the altered exposure of
concomitantly administered substrate drugs. Based on the studies with
natural compounds and derivatives, inhibitors of BCRP tend to show higher
molecular weight, lipophilicity, aromaticity, and number of rings in their
structure than non-inhibitors. Finally, the baculovirus-based expression
system,  combined  with  the  VT  assay  proved  to  be  a  useful  method  for
identifying significantly decreased transport activity and expression of nine
genetic  variants  of  BCRP,  pointing  to  the  functional  importance  of
transmembrane residues in BCRP.
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